p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
integrates	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
rapamycin-regulated	O
signals	O
for	O
E2F	B-protein
regulation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
hematopoietic	B-protein
cytokine	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
uses	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
-induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	B-protein
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	B-protein
3-kinase	I-protein
also	O
regulates	O
the	O
activity	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
,	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
kinase	I-protein
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T-cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T-cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
,	O
IL-2	B-protein
and	O
PI	B-protein
3-kinase	I-protein
activation	O
of	O
E2Fs	B-protein
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL-2	B-protein
-and	O
PI	B-protein
3-kinase	I-protein
-induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	B-protein
transcriptional	O
activity	O
include	O
both	O
rapamycin-resistant	O
and	O
rapamycin-sensitive	O
components	O
.	O

Expression	O
of	O
a	O
rapamycin-resistant	B-protein
mutant	I-protein
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
T	B-cell_type
cells	I-cell_type
could	O
restore	O
rapamycin-suppressed	O
E2F	B-protein
responses	O
.	O

Thus	O
,	O
the	O
rapamycin-controlled	O
processes	O
involved	O
in	O
E2F	B-protein
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
.	O

However	O
,	O
the	O
rapamycin-resistant	B-protein
p70	I-protein
(	I-protein
s6k	I-protein
)	I-protein
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T-cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin-sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T-cell	O
cycle	O
progression	O
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
is	O
able	O
to	O
regulate	O
E2F	B-protein
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	B-protein
receptors	O
,	O
PI	B-protein
3-kinase	I-protein
,	O
and	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

MOLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
July	NULL
1999	NULL
,	NULL
p.	NULL
4729-4738	NULL
0270-7306/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

p70°°*	NULL
Integrates	NULL
Phosphatidylinositol	NULL
3-Kinase	NULL
and	NULL
Rapamycin	NULL
Regulated	NULL
Signals	NULL
for	NULL
E2F	NULL
Regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
PAUL	NULL
BRENNAN	NULL
,	NULL
J.	NULL
W.	NULL
BABBAGE	NULL
,	NULL
'	NULL
G.	NULL
THOMAS	NULL
,	NULL
``	NULL
anp	NULL
DOREEN	NULL
CANTRELL	NULL
'	NULL
!	NULL

*	NULL
Lymphocyte	NULL
Activation	NULL
Laboratory	NULL
,	NULL
Imperial	NULL
Cancer	NULL
Research	NULL
Fund	NULL
,	NULL
London	NULL
WC2A	NULL
3PX	NULL
,	NULL
United	NULL
Kingdom	NULL
,	NULL
``	NULL
and	NULL
Friedrich	NULL
Miescher	NULL
Institute	NULL
,	NULL
CH-4002	NULL
Basel	NULL
,	NULL
Switzerland	NULL
``	NULL
Received	NULL
14	NULL
September	NULL
1998/Returned	NULL
for	NULL
modification	NULL
16	NULL
November	NULL
1998/Accepted	NULL
22	NULL
April	NULL
1999	NULL
In	NULL
T	NULL
lymphocytes	NULL
,	NULL
the	NULL
hematopoietic	NULL
cytokine	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
uses	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI	NULL
3-kinase	NULL
)	NULL
-induced	NULL
signaling	NULL
pathways	NULL
to	NULL
regulate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
,	NULL
a	NULL
critical	NULL
cell	NULL
cycle	NULL
checkpoint	NULL
.	NULL

PI	NULL
3-kinase	NULL
also	NULL
regulates	NULL
the	NULL
activity	NULL
of	NULL
p70°°®	NULL
,	NULL
the	NULL
408	NULL
ribosomal	NULL
protein	NULL
S6	NULL
kinase	NULL
,	NULL
a	NULL
response	NULL
that	NULL
is	NULL
abrogated	NULL
by	NULL
the	NULL
macrolide	NULL
rapamycin	NULL
.	NULL

This	NULL
immunosuppressive	NULL
drug	NULL
is	NULL
known	NULL
to	NULL
prevent	NULL
T-cell	NULL
proliferation	NULL
,	NULL
but	NULL
the	NULL
precise	NULL
point	NULL
at	NULL
which	NULL
rapamycin	NULL
regulates	NULL
T-cell	NULL
cycle	NULL
progression	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
,	NULL
and	NULL
the	NULL
role	NULL
of	NULL
p70°	NULL
``	NULL
*	NULL
in	NULL
,	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
activation	NULL
of	NULL
E2Fs	NULL
have	NULL
not	NULL
been	NULL
characterized	NULL
.	NULL

Our	NULL
present	NULL
results	NULL
show	NULL
that	NULL
IL-2-	NULL
and	NULL
PI	NULL
3-kinase-induced	NULL
pathways	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
include	NULL
both	NULL
rapamycin-resistant	NULL
and	NULL
rapamycin-sensitive	NULL
components	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70°°®	NULL
in	NULL
T	NULL
cells	NULL
could	NULL
restore	NULL
rapamycin-suppressed	NULL
E2F	NULL
responses	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
rapamycin-controlled	NULL
processes	NULL
involved	NULL
in	NULL
E2F	NULL
regulation	NULL
appear	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
p70®°®	NULL
.	NULL

However	NULL
,	NULL
the	NULL
rapamycin-resistant	NULL
p70°°*	NULL
could	NULL
not	NULL
rescue	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
T-cell	NULL
cycle	NULL
entry	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
involvement	NULL
of	NULL
additional	NULL
,	NULL
rapamycin-sensitive	NULL
pathways	NULL
in	NULL
the	NULL
control	NULL
of	NULL
T-cell	NULL
cycle	NULL
progression	NULL
.	NULL

The	NULL
present	NULL
results	NULL
thus	NULL
show	NULL
that	NULL
p70°*	NULL
is	NULL
able	NULL
to	NULL
regulate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
and	NULL
provide	NULL
direct	NULL
evidence	NULL
for	NULL
the	NULL
first	NULL
time	NULL
for	NULL
a	NULL
link	NULL
between	NULL
IL-2	NULL
receptors	NULL
,	NULL
PI	NULL
3-kinase	NULL
,	NULL
and	NULL
p70°*	NULL
that	NULL
regulates	NULL
a	NULL
crucial	NULL
G	NULL
,	NULL
checkpoint	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
cytokine	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
controls	NULL
T-cell	NULL
cycle	NULL
progression	NULL
and	NULL
differentiation	NULL
.	NULL

The	NULL
essential	NULL
and	NULL
irreplaceable	NULL
functions	NULL
of	NULL
IL-2	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
and	NULL
the	NULL
potential	NULL
use	NULL
of	NULL
this	NULL
cytokine	NULL
in	NULL
immunotherapy	NULL
has	NULL
prompted	NULL
clinical	NULL
and	NULL
pharmacological	NULL
interest	NULL
in	NULL
IL-2	NULL
signal	NULL
transduction	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Triggering	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
activates	NULL
the	NULL
Janus	NULL
kinases	NULL
(	NULL
JAKs	NULL
)	NULL
1	NULL
and	NULL
3	NULL
(	NULL
1	NULL
,	NULL
20	NULL
,	NULL
29	NULL
,	NULL
37	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Signaling	NULL
cascades	NULL
initiated	NULL
by	NULL
the	NULL
action	NULL
of	NULL
these	NULL
IL-2-induced	NULL
tyrosine	NULL
kinases	NULL
include	NULL
activation	NULL
of	NULL
Ras	NULL
effector	NULL
pathways	NULL
(	NULL
11	NULL
,	NULL
18	NULL
,	NULL
45	NULL
)	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
STAT	NULL
's	NULL
3	NULL
and	NULL
5	NULL
(	NULL
2	NULL
,	NULL
17	NULL
,	NULL
21	NULL
,	NULL
24	NULL
)	NULL
,	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI	NULL
3-kinase	NULL
)	NULL
and	NULL
the	NULL
kinase	NULL
Akt	NULL
,	NULL
also	NULL
called	NULL
protein	NULL
kinase	NULL
B	NULL
(	NULL
PKB	NULL
)	NULL
(	NULL
34	NULL
,	NULL
36	NULL
)	NULL
.	NULL

A	NULL
key	NULL
event	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
an	NULL
important	NULL
checkpoint	NULL
for	NULL
mitogenesis	NULL
is	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
E2Fs	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Sites	NULL
for	NULL
EZ2F	NULL
binding	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
many	NULL
genes	NULL
important	NULL
for	NULL
cell	NULL
cycle	NULL
regulation	NULL
,	NULL
such	NULL
as	NULL
the	NULL
cyclin	NULL
E	NULL
gene	NULL
(	NULL
4	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
examined	NULL
the	NULL
signaling	NULL
pathways	NULL
used	NULL
by	NULL
IL-2	NULL
to	NULL
regulate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
and	NULL
have	NULL
established	NULL
that	NULL
PI	NULL
3-kinase	NULL
has	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
coupling	NULL
the	NULL
IL-2	NULL
receptor	NULL
to	NULL
E2F	NULL
regulation	NULL
.	NULL

In	NULL
quiescent	NULL
G/G	NULL
,	NULL
-arrested	NULL
cells	NULL
,	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2Fs	NULL
is	NULL
repressed	NULL
by	NULL
their	NULL
binding	NULL
of	NULL
a	NULL
pocket	NULL
protein	NULL
,	NULL
of	NULL
which	NULL
three	NULL
have	NULL
been	NULL
identified	NULL
:	NULL
pRb	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
p130	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
between	NULL
pocket	NULL
proteins	NULL
and	NULL
E2Fs	NULL
are	NULL
controlled	NULL
by	NULL
protein	NULL
phosphorylation	NULL
:	NULL
cyclin-cyclin-dependent	NULL
kinase	NULL
(	NULL
edk	NULL
)	NULL
-medi-ated	NULL
phosphorylation	NULL
of	NULL
pocket	NULL
proteins	NULL
results	NULL
in	NULL
the	NULL
release	NULL
of	NULL
E2F	NULL
,	NULL
resulting	NULL
in	NULL
loss	NULL
of	NULL
E2F	NULL
repressor	NULL
function	NULL
,	NULL
and	NULL
allows	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

In	NULL
T	NULL
lymphocytes	NULL
,	NULL
PI	NULL
3-kinase	NULL
signals	NULL
control	NULL
pRb	NULL
and	NULL
p130	NULL
hyperphosphorylation	NULL
(	NULL
5	NULL
)	NULL
,	NULL
which	NULL
is	NULL
regulated	NULL
by	NULL
cyclin	NULL
D-cdk	NULL
complexes	NULL
.	NULL

In	NULL
turn	NULL
,	NULL
PI	NULL
3-kinase	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Lymphocyte	NULL
Activation	NULL
Laboratory	NULL
,	NULL
Imperial	NULL
Cancer	NULL
Research	NULL
Fund	NULL
,	NULL
Room	NULL
105	NULL
,	NULL
44	NULL
Lincoln	NULL
's	NULL
Inn	NULL
Fields	NULL
,	NULL
London	NULL
WCZA	NULL
3PX	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

Phone	NULL
:	NULL
44	NULL
171	NULL
269	NULL
3307	NULL
.	NULL

Fax	NULL
:	NULL
44	NULL
171	NULL
269	NULL
2831	NULL
.	NULL

E-mail	NULL
:	NULL
cantrell	NULL
@	NULL
icrf.icnet.uk	NULL
.	NULL

4729	NULL
signals	NULL
are	NULL
required	NULL
for	NULL
IL-2	NULL
upregulation	NULL
of	NULL
cyclin	NULL
D3	NULL
.	NULL

Moreover	NULL
,	NULL
PI	NULL
3-kinase	NULL
signaling	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
EZ2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
PI	NULL
3-kinase	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
and	NULL
hence	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
E2Fs	NULL
explains	NULL
why	NULL
activation	NULL
of	NULL
this	NULL
lipid	NULL
kinase	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
proliferative	NULL
responses	NULL
of	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
proximal	NULL
effectors	NULL
of	NULL
PI	NULL
3-kinase	NULL
that	NULL
regulate	NULL
E2Fs	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
characterized	NULL
.	NULL

PI	NULL
3-kinase	NULL
signaling	NULL
pathways	NULL
previously	NULL
described	NULL
in	NULL
T	NULL
cells	NULL
include	NULL
the	NULL
MEK/ERK2	NULL
pathway	NULL
(	NULL
22	NULL
)	NULL
.	NULL

However	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
ERKs	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
IL-2	NULL
activation	NULL
of	NULL
E2Fs	NULL
,	NULL
excluding	NULL
this	NULL
pathway	NULL
from	NULL
any	NULL
critical	NULL
role	NULL
in	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
(	NULL
5	NULL
)	NULL
.	NULL

PI	NULL
3-kinase	NULL
also	NULL
couples	NULL
the	NULL
IL-2	NULL
receptor	NULL
to	NULL
signaling	NULL
pathways	NULL
inhibited	NULL
by	NULL
the	NULL
drug	NULL
rapamycin	NULL
(	NULL
34	NULL
)	NULL
,	NULL
a	NULL
powerful	NULL
and	NULL
important	NULL
immunosuppressant	NULL
that	NULL
blocks	NULL
T-cell	NULL
proliferation	NULL
.	NULL

The	NULL
distal	NULL
signaling	NULL
pathways	NULL
regulated	NULL
by	NULL
rapamycin	NULL
that	NULL
explain	NULL
its	NULL
antiproliferative	NULL
actions	NULL
in	NULL
T	NULL
cells	NULL
have	NULL
not	NULL
been	NULL
characterized	NULL
.	NULL

Rapamycin	NULL
forms	NULL
an	NULL
inhibitory	NULL
complex	NULL
with	NULL
the	NULL
immunophi-lin	NULL
FKBP12	NULL
,	NULL
and	NULL
this	NULL
complex	NULL
regulates	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
protein	NULL
termed	NULL
mTOR	NULL
(	NULL
mammalian	NULL
target	NULL
for	NULL
rapamycin	NULL
)	NULL
which	NULL
has	NULL
homology	NULL
to	NULL
protein	NULL
and	NULL
lipid	NULL
kinases	NULL
(	NULL
6	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Direct	NULL
targets	NULL
for	NULL
mTOR	NULL
,	NULL
including	NULL
the	NULL
initiation	NULL
factor	NULL
46	NULL
binding	NULL
protein	NULL
1	NULL
(	NULL
4EBP1	NULL
)	NULL
(	NULL
7	NULL
)	NULL
,	NULL
a	NULL
repressor	NULL
of	NULL
eukaryotic	NULL
initiation	NULL
factor	NULL
4E	NULL
(	NULL
eIF4E	NULL
)	NULL
,	NULL
have	NULL
been	NULL
described	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
4EBP1	NULL
releases	NULL
the	NULL
protein	NULL
from	NULL
eIF4E	NULL
,	NULL
allowing	NULL
the	NULL
initiation	NULL
factor	NULL
to	NULL
form	NULL
a	NULL
productive	NULL
mRNA	NULL
cap	NULL
binding	NULL
complex	NULL
.	NULL

Rapamycin	NULL
interactions	NULL
with	NULL
mTOR	NULL
also	NULL
regulate	NULL
the	NULL
activity	NULL
of	NULL
p70	NULL
,	NULL
the	NULL
kinase	NULL
that	NULL
phosphorylates	NULL
the	NULL
408	NULL
ribosomal	NULL
protein	NULL
$	NULL
6	NULL
(	NULL
44	NULL
)	NULL
.	NULL

S6	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
only	NULL
p70®*	NULL
substrate	NULL
,	NULL
and	NULL
by	NULL
controlling	NULL
S6	NULL
phosphorylation	NULL
,	NULL
p70°*	NULL
regulates	NULL
the	NULL
translation	NULL
of	NULL
an	NULL
essential	NULL
family	NULL
of	NULL
mRNAs	NULL
that	NULL
contain	NULL
an	NULL
oligopyrimidine	NULL
tract	NULL
at	NULL
their	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
mRNA	NULL
subset	NULL
includes	NULL
transcripts	NULL
encoding	NULL
ribosomal	NULL
proteins	NULL
and	NULL
protein	NULL
synthesis	NULL
elongation	NULL
factors	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
p70®*	NULL
in	NULL
the	NULL
4730	NULL
BRENNAN	NULL
ET	NULL
AL	NULL
.	NULL

suppressive	NULL
actions	NULL
of	NULL
rapamycin	NULL
on	NULL
cell	NULL
proliferation	NULL
has	NULL
been	NULL
the	NULL
subject	NULL
of	NULL
much	NULL
debate	NULL
.	NULL

Recent	NULL
analysis	NULL
of	NULL
embryonic	NULL
stem	NULL
cells	NULL
containing	NULL
a	NULL
targeted	NULL
deletion	NULL
of	NULL
p70°*	NULL
showed	NULL
that	NULL
loss	NULL
of	NULL
this	NULL
enzyme	NULL
did	NULL
not	NULL
cause	NULL
a	NULL
change	NULL
in	NULL
the	NULL
rapamycin	NULL
sensitivity	NULL
of	NULL
proliferative	NULL
responses	NULL
(	NULL
23	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
new	NULL
S6	NULL
kinase	NULL
gene	NULL
,	NULL
termed	NULL
p70®°*	NULL
,	NULL
which	NULL
contains	NULL
all	NULL
the	NULL
same	NULL
regulatory	NULL
motifs	NULL
and	NULL
rapamycin-regulated	NULL
phosphorylation	NULL
sites	NULL
as	NULL
p70°	NULL
``	NULL
®	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
identified	NULL
.	NULL

p70®°*	NULL
catalytic	NULL
activity	NULL
,	NULL
like	NULL
that	NULL
of	NULL
p70°°®	NULL
,	NULL
is	NULL
fully	NULL
suppressed	NULL
by	NULL
rapamycin	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
rapamycin	NULL
sensitivity	NULL
of	NULL
p70®°-null	NULL
cells	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
compensating	NULL
,	NULL
rapamycin-sensitive	NULL
,	NULL
functional	NULL
analogue	NULL
of	NULL
p70°®°*	NULL
(	NULL
41	NULL
)	NULL
.	NULL

IL-2	NULL
regulation	NULL
of	NULL
p70°°*	NULL
and	NULL
E2Fs	NULL
are	NULL
both	NULL
controlled	NULL
by	NULL
PI	NULL
3-kinase	NULL
.	NULL

Moreover	NULL
,	NULL
PI	NULL
3-kinase	NULL
signals	NULL
alone	NULL
are	NULL
sufficient	NULL
to	NULL
drive	NULL
activation	NULL
of	NULL
p70°°®	NULL
,	NULL
just	NULL
as	NULL
they	NULL
are	NULL
sufficient	NULL
to	NULL
switch	NULL
on	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

p70°®*	NULL
is	NULL
therefore	NULL
a	NULL
potential	NULL
candidate	NULL
to	NULL
mediate	NULL
PI	NULL
3-kinase	NULL
responses	NULL
for	NULL
E2F	NULL
regulation	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
it	NULL
is	NULL
well	NULL
documented	NULL
that	NULL
rapamycin	NULL
,	NULL
which	NULL
abrogates	NULL
activity	NULL
,	NULL
has	NULL
an	NULL
antiproliferative	NULL
effect	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

Rapamycin	NULL
blocks	NULL
T-cell	NULL
proliferation	NULL
by	NULL
delaying	NULL
G	NULL
;	NULL
,	NULL
transit	NULL
times	NULL
rather	NULL
than	NULL
by	NULL
causing	NULL
an	NULL
absolute	NULL
mitotic	NULL
block	NULL
(	NULL
43	NULL
)	NULL
.	NULL

If	NULL
rapamycin	NULL
signaling	NULL
pathways	NULL
were	NULL
important	NULL
for	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
activation	NULL
of	NULL
E2Fs	NULL
,	NULL
then	NULL
this	NULL
would	NULL
be	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
this	NULL
drug	NULL
on	NULL
T-cell	NULL
clonal	NULL
expansion	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
the	NULL
phosphorylation	NULL
of	NULL
the	NULL
pocket	NULL
proteins	NULL
(	NULL
9	NULL
,	NULL
14	NULL
)	NULL
,	NULL
but	NULL
these	NULL
have	NULL
generally	NULL
been	NULL
performed	NULL
with	NULL
nonlymphoid	NULL
cells	NULL
and	NULL
have	NULL
yielded	NULL
discrepant	NULL
results	NULL
.	NULL

Rapamycin	NULL
has	NULL
also	NULL
been	NULL
described	NULL
to	NULL
prevent	NULL
IL-2-induced	NULL
loss	NULL
of	NULL
the	NULL
cyclin-edk	NULL
inhibitor	NULL
p27	NULL
``	NULL
(	NULL
32	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
targeted	NULL
degradation	NULL
of	NULL
p27	NULL
?	NULL
``	NULL

is	NULL
initiated	NULL
by	NULL
cyclin	NULL
E-cdk2	NULL
phosphorylation	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
if	NULL
rapamycin-treated	NULL
T	NULL
cells	NULL
fail	NULL
to	NULL
correctly	NULL
activate	NULL
cyclin-cdk	NULL
complexes	NULL
,	NULL
then	NULL
p27	NULL
``	NULL
levels	NULL
would	NULL
persist	NULL
but	NULL
as	NULL
a	NULL
consequence	NULL
,	NULL
not	NULL
a	NULL
cause	NULL
,	NULL
of	NULL
failed	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

To	NULL
resolve	NULL
this	NULL
issue	NULL
,	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
IL-2-induced	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
E2Fs	NULL
in	NULL
T	NULL
cells	NULL
are	NULL
required	NULL
.	NULL

The	NULL
objective	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
use	NULL
rapamycin	NULL
and	NULL
mutants	NULL
of	NULL
p70°*	NULL
to	NULL
explore	NULL
the	NULL
role	NULL
of	NULL
p70®*	NULL
in	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
regulation	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
IL-2-	NULL
and	NULL
PI	NULL
3-kinase-induced	NULL
pathways	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
are	NULL
rapamycin	NULL
sensitive	NULL
.	NULL

We	NULL
show	NULL
that	NULL
rapamycin	NULL
abrogates	NULL
IL-2	NULL
activation	NULL
of	NULL
p70®	NULL
.	NULL

Overexpression	NULL
of	NULL
wild-type	NULL
p70°°	NULL
,	NULL
but	NULL
not	NULL
that	NULL
of	NULL
a	NULL
kinase-dead	NULL
mutant	NULL
,	NULL
increased	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
p70°°®	NULL
rapamycin-resistant	NULL
mutant	NULL
rescued	NULL
the	NULL
inhibition	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
by	NULL
rapamycin	NULL
.	NULL

These	NULL
results	NULL
map	NULL
cell	NULL
cycle	NULL
targets	NULL
for	NULL
rapamycin	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

They	NULL
show	NULL
also	NULL
that	NULL
p70°°*	NULL
is	NULL
able	NULL
to	NULL
regulate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
,	NULL
and	NULL
they	NULL
provide	NULL
direct	NULL
evidence	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
controls	NULL
signals	NULL
that	NULL
regulate	NULL
a	NULL
G	NULL
,	NULL
checkpoint	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

IL-2	NULL
was	NULL
supplied	NULL
by	NULL
Chiron	NULL
.	NULL

Rapamycin	NULL
was	NULL
provided	NULL
by	NULL
G.	NULL
Thomas	NULL
.	NULL

[	NULL
'*Clacetyl	NULL
coenzyme	NULL
A	NULL
(	NULL
at	NULL
50	NULL
mCi/mmo	NULL
!	NULL
)	NULL

and	NULL
[	NULL
y-*PJATP	NULL
(	NULL
5,000	NULL
Ci/mmol	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Amersham	NULL
Corp.	NULL
Antibodies	NULL
for	NULL
p130	NULL
,	NULL
E2F-1	NULL
,	NULL
and	NULL
E2F-4	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

Antibodies	NULL
for	NULL
pRb	NULL
were	NULL
obtained	NULL
from	NULL
Pharmingen	NULL
.	NULL

Cell	NULL
culture	NULL
.	NULL

Kit225	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
,	NULL
a	NULL
human	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
,	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
IL-2/ml	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
humidified	NULL
incubator	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
,	NULL
these	NULL
cells	NULL
accumulate	NULL
in	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
transfection	NULL
by	NULL
two	NULL
washes	NULL
in	NULL
RPMI	NULL
medium	NULL
.	NULL

For	NULL
other	NULL
experiments	NULL
the	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
IL-2	NULL
for	NULL
72	NULL
h.	NULL
Human	NULL
peripheral	NULL
blood-derived	NULL
T	NULL
lymphocytes	NULL
were	NULL
generated	NULL
and	NULL
maintained	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Plasmids	NULL
.	NULL

E2ACAT	NULL
,	NULL
originally	NULL
described	NULL
by	NULL
Murthy	NULL
et	NULL
al	NULL
.	NULL

(	NULL
31	NULL
)	NULL
and	NULL
used	NULL
subsequently	NULL
by	NULL
Mann	NULL
and	NULL
Jones	NULL
(	NULL
26	NULL
)	NULL
,	NULL
comprises	NULL
bp	NULL
-284	NULL
to	NULL
+62	NULL
of	NULL
the	NULL
E2A	NULL
promoter	NULL
upstream	NULL
of	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
.	NULL

Two	NULL
E2F	NULL
binding	NULL
sites	NULL
are	NULL
present	NULL
in	NULL
E2ACAT	NULL
(	NULL
the	NULL
first	NULL
is	NULL
between	NULL
-29	NULL
and	NULL
-21	NULL
,	NULL
and	NULL
the	NULL
second	NULL
is	NULL
between	NULL
-82	NULL
and	NULL
-66	NULL
)	NULL
and	NULL
allow	NULL
the	NULL
E2A	NULL
promoter	NULL
to	NULL
report	NULL
and	NULL
sensitively	NULL
quantitate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
(	NULL
5	NULL
,	NULL
26	NULL
,	NULL
33	NULL
)	NULL
.	NULL

E2CAT	NULL
(	NULL
E2F	NULL
)	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
J.	NULL
R.	NULL
Nevins	NULL
(	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
Duke	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Durham	NULL
,	NULL
N.C.	NULL
)	NULL
.	NULL

It	NULL
contains	NULL
bp	NULL
-85	NULL
to	NULL
+40	NULL
from	NULL
the	NULL
E2A	NULL
promoter	NULL
,	NULL
in	NULL
which	NULL
both	NULL
E2F	NULL
sites	NULL
have	NULL
been	NULL
mutated	NULL
,	NULL
upstream	NULL
of	NULL
a	NULL
CAT	NULL
gene	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
reporter	NULL
plasmid	NULL
GRRCAT	NULL
contains	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
gamma	NULL
interferon	NULL
receptor	NULL
response	NULL
element	NULL
upstream	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
-CAT	NULL
gene	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
following	NULL
expression	NULL
plasmids	NULL
have	NULL
been	NULL
described	NULL
elsewhere	NULL
:	NULL
pEF	NULL
,	NULL
expressing	NULL
rCD2p110	NULL
(	NULL
35	NULL
)	NULL
;	NULL
a	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
plasmid	NULL
expressing	NULL
myc-tagged	NULL
wild-type	NULL
p70°*	NULL
(	NULL
19	NULL
)	NULL
;	NULL
a	NULL
CMV	NULL
plasmid	NULL
expressing	NULL
myc-tagged	NULL
rapamycin-resistant	NULL
p70	NULL
(	NULL
19	NULL
)	NULL
;	NULL
p70**Q	NULL
;	NULL
,	NULL
,	NULL
,	NULL
expressing	NULL
myc-tagged	NULL
kinase-dead	NULL
p70®*	NULL
(	NULL
19	NULL
)	NULL
;	NULL
and	NULL
pRbA	NULL
(	NULL
pEF	NULL
)	NULL
,	NULL
an	NULL
Rb	NULL
construct	NULL
in	NULL
which	NULL
the	NULL
p34	NULL
``	NULL
phosphorylation	NULL
sites	NULL
are	NULL
mutated	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
purified	NULL
by	NULL
cesium	NULL
chloride	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

E2A	NULL
DNA	NULL
affinity	NULL
precipitations	NULL
.	NULL

For	NULL
affinity	NULL
precipitation	NULL
of	NULL
E2Fs	NULL
from	NULL
T-cell	NULL
lysates	NULL
,	NULL
biotinylated	NULL
double-stranded	NULL
oligonucleotides	NULL
which	NULL
corresponded	NULL
to	NULL
the	NULL
E2F	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
E2A	NULL
promoter	NULL
(	NULL
TAGTITTCGCGCTTAAATITGAG	NULL
AAAGGGCGCGAAACTAGTC	NULL
[	NULL
E2F	NULL
binding	NULL
sites	NULL
are	NULL
underlined	NULL
]	NULL
)	NULL
were	NULL
syn-thesized	NULL
.	NULL

A	NULL
mutant	NULL
oligonucleotide	NULL
,	NULL
in	NULL
which	NULL
two	NULL
nucleotides	NULL
in	NULL
each	NULL
E2F	NULL
binding	NULL
site	NULL
were	NULL
mutated	NULL
(	NULL
shown	NULL
in	NULL
boldface	NULL
)	NULL
,	NULL
was	NULL
used	NULL
to	NULL
check	NULL
the	NULL
specificity	NULL
of	NULL
binding	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
TAGTITTCGATCTTAAAT	NULL
TTGAGAAAGGGTACGAAACTAGTC	NULL
.	NULL

Briefly	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
NP-40	NULL
)	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
1	NULL
%	NULL
NP-40	NULL
,	NULL
150	NULL
mM	NULL
NaC	NULL
]	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
aprotinin/ml	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
leupeptin/ml	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
chymostatin/ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

DNA	NULL
binding	NULL
proteins	NULL
were	NULL
isolated	NULL
from	NULL
extracts	NULL
by	NULL
incubation	NULL
at	NULL
4°C	NULL
for	NULL
2	NULL
h	NULL
with	NULL
1	NULL
pg	NULL
of	NULL
double-stranded	NULL
,	NULL
5'-biotinylated	NULL
oligonucleotide	NULL
coupled	NULL
to	NULL
30	NULL
pl	NULL
of	NULL
a	NULL
50	NULL
%	NULL
suspension	NULL
of	NULL
streptavidin	NULL
agarose	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Complexes	NULL
were	NULL
washed	NULL
twice	NULL
,	NULL
after	NULL
which	NULL
protein	NULL
was	NULL
eluted	NULL
from	NULL
the	NULL
beads	NULL
with	NULL
reducing	NULL
sample	NULL
buffer	NULL
.	NULL

Samples	NULL
were	NULL
resolved	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electro-phoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
(	NULL
7.5	NULL
%	NULL
polyacrylamide	NULL
)	NULL
.	NULL

E2A	NULL
DNA	NULL
binding	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
and	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

For	NULL
competing	NULL
affinity-purified	NULL
complexes	NULL
,	NULL
a	NULL
double-stranded	NULL
E2F	NULL
oligonucleotide	NULL
(	NULL
not	NULL
biotinylated	NULL
)	NULL
with	NULL
the	NULL
sequence	NULL
ATTTAAGTTTCGCGCC	NULL
CTTTCCAA	NULL
(	NULL
30	NULL
)	NULL
was	NULL
used	NULL
.	NULL

Samples	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
oligonucleotide	NULL
for	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
biotinylated	NULL
oligonucleotide	NULL
.	NULL

p70°	NULL
``	NULL
*	NULL
assays	NULL
.	NULL

p70°*	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
a	NULL
method	NULL
described	NULL
by	NULL
Reif	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
myc	NULL
epitope-tagged	NULL
S6	NULL
kinase	NULL
(	NULL
S6k	NULL
)	NULL
constructs	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
maintained	NULL
under	NULL
normal	NULL
growth	NULL
conditions	NULL
for	NULL
16	NULL
h	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
rapamycin	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Treatment	NULL
was	NULL
terminated	NULL
by	NULL
placing	NULL
the	NULL
samples	NULL
on	NULL
ice	NULL
;	NULL
they	NULL
were	NULL
then	NULL
centrifuged	NULL
and	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
120	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
20	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
benzamidine	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
6	NULL
mM	NULL
EGTA	NULL
,	NULL
7.5	NULL
mM	NULL
inorganic	NULL
pyrophos-phate	NULL
,	NULL
15	NULL
mM	NULL
p-nitrophenyl	NULL
phosphate	NULL
,	NULL
1	NULL
%	NULL
NP-40	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
0.1	NULL
mM	NULL
Na	NULL
;	NULL
VO	NULL
,	NULL
)	NULL
.	NULL

Postnuclear	NULL
lysates	NULL
were	NULL
precleared	NULL
with	NULL
protein	NULL
A	NULL
cell	NULL
suspension	NULL
(	NULL
Sigma	NULL
)	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
15	NULL
ug	NULL
of	NULL
9E10	NULL
antibody	NULL
precoupled	NULL
to	NULL
protein	NULL
G-Sepharose	NULL
beads	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
lysis	NULL
buffer	NULL
and	NULL
once	NULL
in	NULL
p70®**	NULL
assay	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
morpholinepropanesulfonic	NULL
acid	NULL
[	NULL
MOPS	NULL
]	NULL
[	NULL
pH	NULL
7.2	NULL
]	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
;	NULL
,	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
and	NULL
were	NULL
assayed	NULL
for	NULL
kinase	NULL
activity	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
28	NULL
)	NULL
by	NULL
using	NULL
408	NULL
ribosomal	NULL
protein	NULL
S6	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

Proteins	NULL
were	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

*°P-labelled	NULL
S6	NULL
proteins	NULL
were	NULL
detected	NULL
by	NULL
autoradiography	NULL
or	NULL
quantitated	NULL
with	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
myc	NULL
epitope-tagged	NULL
p70°°*	NULL
was	NULL
revealed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
the	NULL
mye	NULL
epitope-specific	NULL
antibody	NULL
9E10	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assay	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
IL-2	NULL
as	NULL
indicated	NULL
prior	NULL
to	NULL
transfection	NULL
,	NULL
and	NULL
15	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
the	NULL
amounts	NULL
of	NULL
DNA	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
.	NULL

Electroporation	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
Gene	NULL
Pulser	NULL
(	NULL
Bio-Rad	NULL
)	NULL
set	NULL
at	NULL
320	NULL
V	NULL
and	NULL
960	NULL
pF	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
replaced	NULL
in	NULL
culture	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
IL-2/ml	NULL
for	NULL
16	NULL
to	NULL
18	NULL
h	NULL
prior	NULL
to	NULL
lysis	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
0.65	NULL
%	NULL
NP-40	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
by	NULL
the	NULL
radioisotope	NULL
method	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
``	NULL
per	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
containing	NULL
25	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
75	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
%	NULL
NP-40	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
aprotinin/ml	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
leupeptin/ml	NULL
,	NULL
1	NULL
g	NULL
of	NULL
chymostatin/ml	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
Na	NULL
;	NULL
VOs	NULL
;	NULL
.	NULL

Proteins	NULL
were	NULL
concentrated	NULL
by	NULL
precipitation	NULL
with	NULL
1.5	NULL
volumes	NULL
of	NULL
acetone	NULL
.	NULL

Proteins	NULL
from	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
using	NULL
the	NULL
following	NULL
gel	NULL
conditions	NULL
:	NULL
for	NULL
E2F	NULL
and	NULL
pocket	NULL
proteins	NULL
,	NULL
7.5	NULL
%	NULL
acrylamide-0.2	NULL
%	NULL
bis	NULL
,	NULL
and	NULL
for	NULL
S6kinase	NULL
,	NULL
10	NULL
%	NULL
acryl-amide-0.16	NULL
%	NULL
bis	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
membranes	NULL
and	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
antibodies	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figures	NULL
by	NULL
using	NULL
the	NULL
ECL	NULL
detection	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Dual	NULL
staining	NULL
for	NULL
BrdU	NULL
and	NULL
myc-tagged	NULL
p70®**	NULL
.	NULL

Quiesced	NULL
Kit225	NULL
cells	NULL
were	NULL
transfected	NULL
and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
.	NULL

They	NULL
were	NULL
then	NULL
labelled	NULL
overnight	NULL
with	NULL
bromodeoxyuridine	NULL
(	NULL
BrdU	NULL
)	NULL
.	NULL

Following	NULL
labelling	NULL
they	NULL
were	NULL
harvested	NULL
,	NULL
fixed	NULL
in	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
2	NULL
M	NULL
HCI-0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

myc-tagged	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
was	NULL
detected	NULL
with	NULL
a	NULL
biotinylated	NULL
9E10	NULL
antibody	NULL
(	NULL
1.7	NULL
pg/ml	NULL
)	NULL
and	NULL
revealed	NULL
with	NULL
avidin-conjugated	NULL
Tricolour	NULL
(	NULL
Caltag	NULL
)	NULL
.	NULL

BrdU	NULL
was	NULL
detected	NULL
with	NULL
directly	NULL
conjugated	NULL
fluorescein	NULL
isothiocyanate-labelled	NULL
antibody	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
with	NULL
a	NULL
Becton	NULL
Dickinson	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
.	NULL

RESULTS	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
control	NULL
E2F	NULL
activity	NULL
by	NULL
rapamycin-sensitive	NULL
pathways	NULL
.	NULL

IL-2	NULL
regulates	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2Fs	NULL
by	NULL
PI	NULL
3-kinase-mediated	NULL
signals	NULL
(	NULL
5	NULL
)	NULL
.	NULL

To	NULL
monitor	NULL
EZ2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
used	NULL
EZ2ACAT	NULL
,	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
two	NULL
E2F	NULL
binding	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
26	NULL
,	NULL
31	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
Kit225	NULL
was	NULL
used	NULL
in	NULL
these	NULL
transfection	NULL
experiments	NULL
because	NULL
these	NULL
cells	NULL
are	NULL
dependent	NULL
on	NULL
IL-2	NULL
for	NULL
mitosis	NULL
but	NULL
not	NULL
for	NULL
survival	NULL
.	NULL

Kit225	NULL
cells	NULL
are	NULL
like	NULL
normal	NULL
peripheral	NULL
blood-derived	NULL
T	NULL
lymphoblasts	NULL
in	NULL
that	NULL
they	NULL
proliferate	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
serum	NULL
and	NULL
IL-2	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
serum	NULL
,	NULL
the	NULL
cells	NULL
apoptose	NULL
,	NULL
whereas	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
,	NULL
they	NULL
arrest	NULL
in	NULL
G	NULL
,	NULL
.	NULL

Importantly	NULL
,	NULL
after	NULL
IL-2	NULL
deprivation	NULL
and	NULL
G	NULL
;	NULL
,	NULL
arrest	NULL
,	NULL
Kit225	NULL
cells	NULL
remain	NULL
IL-2	NULL
responsive	NULL
for	NULL
cell	NULL
growth	NULL
following	NULL
transient	NULL
transfection	NULL
.	NULL

The	NULL
selectivity	NULL
and	NULL
sensitivity	NULL
of	NULL
EZACAT	NULL
for	NULL
detecting	NULL
transcrip-tionally	NULL
active	NULL
E2Fs	NULL
in	NULL
IL-2-activated	NULL
Kit225	NULL
cells	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
,	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
,	NULL
and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
.	NULL

E2F	NULL
activity	NULL
is	NULL
low	NULL
in	NULL
IL-2-deprived	NULL
Kit225	NULL
cells	NULL
,	NULL
but	NULL
it	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

These	NULL
data	NULL
also	NULL
show	NULL
that	NULL
expression	NULL
of	NULL
CD2p110	NULL
,	NULL
a	NULL
membrane-targeted	NULL
catalytic	NULL
subunit	NULL
of	NULL
PI	NULL
3-kinase	NULL
that	NULL
constitutively	NULL
induces	NULL
accumulation	NULL
of	NULL
PI	NULL
,	NULL
;	NULL
,	NULL
P	NULL
;	NULL
and	NULL
PI	NULL
,	NULL
;	NULL
4	NULL
5	NULL
,	NULL
P	NULL
;	NULL
in	NULL
vivo	NULL
,	NULL
activates	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

An	NULL
E2CAT	NULL
construct	NULL
containing	NULL
the	NULL
-85-to-+40	NULL
portion	NULL
of	NULL
the	NULL
E2A	NULL
promoter	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
E2F	NULL
binding	NULL
sites	NULL
[	NULL
EZ2CAT	NULL
(	NULL
EZF	NULL
)	NULL
]	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
either	NULL
IL-2	NULL
or	NULL
PI	NULL
3-kinase	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
activation	NULL
of	NULL
the	NULL
E2ACAT	NULL
reporter	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
integrity	NULL
of	NULL
E2F	NULL
binding	NULL
sites	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
PI	NULL
3-kinase	NULL
initiates	NULL
responses	NULL
controlled	NULL
by	NULL
the	NULL
rapamycin	NULL
target	NULL
,	NULL
mTOR	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
rapamycin-controlled	NULL
signaling	NULL
pathways	NULL
impinge	NULL
on	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
regulation	NULL
of	NULL
E2Fs	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
E2ACAT	NULL
responses	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
deprived	NULL
of	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
,	NULL
transfected	NULL
with	NULL
EZ2ACAT	NULL
,	NULL
allowed	NULL
to	NULL
recover	NULL
for	NULL
2	NULL
h	NULL
,	NULL
and	NULL
pretreated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
rapamycin	NULL
prior	NULL
to	NULL
IL-2	NULL
addition	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
E2ACAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

IL-2	NULL
induction	NULL
of	NULL
E2ACAT	NULL
shows	NULL
a	NULL
maximal	NULL
response	NULL
at	NULL
5	NULL
to	NULL
10	NULL
ng/ml	NULL
,	NULL
with	NULL
a	NULL
half-maximal	NULL
response	NULL
at	NULL
0.2	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

These	NULL
levels	NULL
of	NULL
IL-2	NULL
correspond	NULL
to	NULL
those	NULL
that	NULL
occupy	NULL
the	NULL
high-affinity	NULL
IL-2	NULL
receptor	NULL
and	NULL
induce	NULL
proliferation	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
show	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
an	NULL
IL-2	NULL
dose	NULL
response	NULL
for	NULL
E2F	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
rapamycin	NULL
treatment	NULL
suppresses	NULL
IL-2	NULL
activation	NULL
of	NULL
EZ2ACAT	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
specificity	NULL
of	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
E2ACAT	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
this	NULL
drug	NULL
on	NULL
IL-2-induced	NULL
phosphorylation	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
STATS	NULL
.	NULL

IL-2	NULL
induces	NULL
rapid	NULL
and	NULL
sustained	NULL
tyrosine	NULL
and	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT5B	NULL
,	NULL
which	NULL
results	NULL
in	NULL
nuclear	NULL
translo-cation	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Quiescent	NULL
Kit225	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
for	NULL
20	NULL
min	NULL
and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

STATS5B	NULL
hyperphosphorylation	NULL
was	NULL
monitored	NULL
by	NULL
examining	NULL
its	NULL
electrophoretic	NULL
mobility	NULL
in	NULL
SDS-PAGE	NULL
,	NULL
with	NULL
the	NULL
upper	NULL
band	NULL
corresponding	NULL
with	NULL
phosphorylated	NULL
STATS5B	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

1C	NULL
show	NULL
that	NULL
20	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
did	NULL
not	NULL
prevent	NULL
IL-2	NULL
induction	NULL
of	NULL
STATS	NULL
hyperphosphorylation	NULL
.	NULL

STATS	NULL
tran	NULL
p70°	NULL
``	NULL
,	NULL
RAPAMYCIN	NULL
,	NULL
AND	NULL
E2F	NULL
|	NULL
4731	NULL
J	NULL
»	NULL
B	NULL
IH	NULL
i1c-2	NULL
G	NULL
[	NULL
]	NULL
Con	NULL
310	NULL
15	NULL
H	NULL
-	NULL
>	NULL
3	NULL
O	NULL
IL-2	NULL
+	NULL
Rap	NULL
>	NULL
a	NULL
C	NULL
co2pi10	NULL
5	NULL
8	NULL
5	NULL
&	NULL
>	NULL
.s	NULL
2	NULL
3	NULL
8	NULL
10	NULL
&	NULL
C3	NULL
Z	NULL
8	NULL
s	NULL
€	NULL
t	NULL
&	NULL
al	NULL
<	NULL
4	NULL
ol	NULL
0	NULL
<	NULL
Pyi	NULL
E2ACAT	NULL
E2CAT	NULL
(	NULL
E2F-	NULL
)	NULL
m	NULL
[	NULL
IL2	NULL
]	NULL
(	NULL
ng/ml	NULL
)	NULL
C	NULL
Time	NULL
45	NULL
min	NULL
6	NULL
hours	NULL
24	NULL
hours	NULL
IL2	NULL
to	NULL
Bos	NULL
Bo-	NULL
Bo-	NULL
Bo-	NULL
to-	NULL
+	NULL
Rap	NULL
to-	NULL
tof	NULL
o-	NULL
o-	NULL
Rok	NULL
-	NULL
-	NULL
+o	NULL
STATS	NULL
I	NULL
lume	NULL
M9	NULL
wae	NULL
N	NULL
wa	NULL
HF	NULL
ws	NULL
H	NULL
cae	NULL
H	NULL
ws	NULL
HH	NULL
-y	NULL
|	NULL
#	NULL
00	NULL
wee	NULL
me	NULL
wae	NULL
m	NULL
P	NULL
D	NULL
7	NULL
[	NULL
_	NULL
]	NULL
Con	NULL
Baus	NULL
I	NULL
=	NULL
>	NULL
€	NULL
UGB	NULL
s	NULL
=	NULL
3	NULL
>	NULL
.	NULL

at	NULL
!	NULL

U	NULL
s	NULL
Mos	NULL
3	NULL
pd	NULL
&	NULL
0C	NULL
q	NULL
1	NULL
0	NULL
GRRCAT	NULL
GRRCAT	NULL
+	NULL
-	NULL
GRRCAT	NULL
+	NULL
Rap	NULL
10ng/ml	NULL
_	NULL
Rap	NULL
20ng/ml	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Rapamycin	NULL
inhibits	NULL
IL-2	NULL
activation	NULL
of	NULL
EZACAT	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
cotransfected	NULL
with	NULL
E2ACAT	NULL
or	NULL
the	NULL
mutated	NULL
reporter	NULL
[	NULL
E2CAT	NULL
(	NULL
E2F	NULL
~	NULL
)	NULL
]	NULL
and	NULL
either	NULL
empty	NULL
vector	NULL
or	NULL
CD2p110	NULL
(	NULL
active	NULL
PI	NULL
3-kinase	NULL
)	NULL
(	NULL
20	NULL
pg	NULL
)	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
empty	NULL
vector	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

Open	NULL
bars	NULL
,	NULL
control	NULL
(	NULL
Con	NULL
)	NULL
;	NULL
solid	NULL
bars	NULL
,	NULL
IL-2	NULL
;	NULL
shaded	NULL
bars	NULL
,	NULL
CD2p110	NULL
.	NULL

After	NULL
22	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
(	NULL
open	NULL
circles	NULL
)	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
solid	NULL
squares	NULL
)	NULL
for	NULL
20	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
IL-2	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
5	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
incubated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

as	NULL
indicated	NULL
for	NULL
45	NULL
min	NULL
,	NULL
6	NULL
h	NULL
,	NULL
and	NULL
24	NULL
h.	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
generated	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
STATS	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
GRRCAT	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
20	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

scriptional	NULL
activity	NULL
was	NULL
assessed	NULL
by	NULL
using	NULL
GRRCAT	NULL
,	NULL
a	NULL
reporter	NULL
gene	NULL
with	NULL
five	NULL
STATS	NULL
binding	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
IL-2	NULL
deprived	NULL
for	NULL
24	NULL
h	NULL
,	NULL
transfected	NULL
with	NULL
GRRCAT	NULL
,	NULL
and	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

Rapamycin	NULL
does	NULL
not	NULL
affect	NULL
STATS	NULL
transcriptional	NULL
activity	NULL
in	NULL
IL-Z-activated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
and	NULL
is	NULL
thus	NULL
not	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
IL-2-activated	NULL
transcription	NULL
.	NULL

Rapamycin	NULL
did	NULL
not	NULL
completely	NULL
abrogate	NULL
E2F	NULL
activation	NULL
by	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

From	NULL
nine	NULL
experiments	NULL
,	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
IL-2-induced	NULL
EZ2ACAT	NULL
activity	NULL
was	NULL
consistently	NULL
50	NULL
%	NULL
.	NULL

Hence	NULL
,	NULL
rapamycin	NULL
signaling	NULL
pathways	NULL
are	NULL
clearly	NULL
involved	NULL
in	NULL
E2F	NULL
regulation	NULL
,	NULL
but	NULL
there	NULL
is	NULL
also	NULL
a	NULL
rapamycin-resistant	NULL
component	NULL
of	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
.	NULL

A	NULL
rapamycin	NULL
dose-response	NULL
curve	NULL
confirms	NULL
this	NULL
observation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Figure	NULL
2A	NULL
shows	NULL
that	NULL
doses	NULL
from	NULL
5	NULL
to	NULL
20	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
cause	NULL
a	NULL
reduction	NULL
of	NULL
approximately	NULL
50	NULL
%	NULL
in	NULL
the	NULL
EZ2F	NULL
response	NULL
.	NULL

The	NULL
data	NULL
also	NULL
show	NULL
that	NULL
4732	NULL
BRENNAN	NULL
ET	NULL
AL	NULL
.	NULL

I	NULL
u	NULL
A	NULL
_	NULL
100	NULL
O	NULL
CD2p110	NULL
E	NULL
3	NULL
E	NULL
&	NULL
75	NULL
S	NULL
33	NULL
Z	NULL
so	NULL
|	NULL
3	NULL
``	NULL
3	NULL
wo	NULL
a	NULL
U	NULL
25	NULL
|	NULL
<	NULL
6	NULL
m	NULL
o	NULL
i	NULL
i	NULL
i	NULL
i	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
[	NULL
Rapameyin	NULL
]	NULL
(	NULL
ng/ml	NULL
)	NULL
Time	NULL
45	NULL
min	NULL
6	NULL
hours	NULL
24	NULL
hours	NULL
IL2	NULL
Roo	NULL
B	NULL
e	NULL
B-	NULL
B	NULL
e	NULL
of	NULL
e	NULL
B-	NULL
+	NULL
Rap	NULL
to	NULL
R	NULL
BR	NULL
Bo-	NULL
-	NULL
#	NULL
$	NULL
o	NULL
$	NULL
-	NULL
-	NULL
oto	NULL
oo+	NULL
__	NULL
w	NULL
“	NULL
Cg	NULL
...	NULL
“	NULL
-	NULL
.-~	NULL
Rap	NULL
(	NULL
ng/ml	NULL
)	NULL
0	NULL
10	NULL
2	NULL
0.5	NULL
S6K	NULL
activity	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Rapamycin	NULL
effects	NULL
on	NULL
E2ACAT	NULL
and	NULL
p70®°*	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
and	NULL
with	NULL
either	NULL
20	NULL
pg	NULL
of	NULL
empty	NULL
vector	NULL
(	NULL
solid	NULL
squares	NULL
)	NULL
or	NULL
pEF	NULL
rCD2p110	NULL
(	NULL
active	NULL
PI	NULL
3-kinase	NULL
)	NULL
(	NULL
open	NULL
circles	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
for	NULL
4	NULL
h.	NULL
They	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
transfected	NULL
with	NULL
empty	NULL
vector	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
percentages	NULL
of	NULL
maximum	NULL
activity	NULL
,	NULL
with	NULL
100	NULL
%	NULL
representing	NULL
15	NULL
%	NULL
+	NULL
3	NULL
%	NULL
acetylation	NULL
for	NULL
IL-2	NULL
and	NULL
24	NULL
%	NULL
+	NULL
4	NULL
%	NULL
acetylation	NULL
for	NULL
cells	NULL
cotransfected	NULL
with	NULL
CD2p110	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
5	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
incubated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

as	NULL
indicated	NULL
for	NULL
45	NULL
min	NULL
,	NULL
6	NULL
h	NULL
,	NULL
and	NULL
24	NULL
h.	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
generated	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
S6	NULL
kinase	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
myc	NULL
epitope-tagged	NULL
p70®**	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
overnight	NULL
and	NULL
treated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
rapamycin	NULL
at	NULL
the	NULL
doses	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
,	NULL
the	NULL
expressed	NULL
p70°*	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
myc	NULL
tag-specific	NULL
antibody	NULL
,	NULL
and	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

S6	NULL
substrate	NULL
phosphorylation	NULL
for	NULL
S6	NULL
kinase	NULL
assays	NULL
was	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

rapamycin	NULL
inhibited	NULL
the	NULL
E2ACAT	NULL
activity	NULL
induced	NULL
in	NULL
cells	NULL
expressing	NULL
constitutively	NULL
active	NULL
PI	NULL
3-kinase	NULL
.	NULL

Like	NULL
IL-2-induced	NULL
E2ACAT	NULL
activity	NULL
,	NULL
PI	NULL
3-kinase-induced	NULL
EZACAT	NULL
activity	NULL
is	NULL
inhibited	NULL
only	NULL
partially	NULL
,	NULL
approximately	NULL
50	NULL
%	NULL
,	NULL
by	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

I	NULL
)	NULL
L-2	NULL
activates	NULL
p70°°*	NULL
by	NULL
a	NULL
rapamycin-dependent	NULL
pathway	NULL
(	NULL
34	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
effectiveness	NULL
of	NULL
rapamycin	NULL
in	NULL
the	NULL
E2F	NULL
activity	NULL
experiments	NULL
,	NULL
a	NULL
series	NULL
of	NULL
parallel	NULL
experiments	NULL
was	NULL
performed	NULL
to	NULL
examine	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
drug	NULL
to	NULL
regulate	NULL
p70°°*	NULL
activity	NULL
in	NULL
Kit225	NULL
cells	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
endogenous	NULL
p70®*	NULL
is	NULL
regulated	NULL
by	NULL
multiple	NULL
phosphorylation	NULL
events	NULL
that	NULL
can	NULL
be	NULL
monitored	NULL
by	NULL
the	NULL
reduced	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
this	NULL
enzyme	NULL
in	NULL
SDS-PAGE	NULL
gels	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
show	NULL
that	NULL
in	NULL
quiescent	NULL
Kit225	NULL
cells	NULL
,	NULL
p70®°°*	NULL
migrates	NULL
predominantly	NULL
as	NULL
a	NULL
doublet	NULL
,	NULL
whereas	NULL
in	NULL
IL-2-activated	NULL
cells	NULL
,	NULL
four	NULL
discrete	NULL
phosphoforms	NULL
of	NULL
the	NULL
enzyme	NULL
can	NULL
be	NULL
readily	NULL
discerned	NULL
.	NULL

In	NULL
rapamycin-treated	NULL
cells	NULL
,	NULL
p70°*	NULL
migrates	NULL
as	NULL
a	NULL
single	NULL
band	NULL
corresponding	NULL
to	NULL
the	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
the	NULL
enzyme	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
IL2	NULL
E2F-1	NULL
IL2+Rap	NULL
Somme	NULL
mmm	NULL
emmm	NULL
*	NULL
B	NULL
Lysate	NULL
EZA-AP	NULL
mutant	NULL
E2A-AP	NULL
E2A-AP	NULL
+comp	NULL
C	NULL
IL2	NULL
<	NULL
p	NULL
co	NULL
wm	NULL
»	NULL
a	NULL
»	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Rapamycin	NULL
and	NULL
E2F	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
10®	NULL
per	NULL
ml	NULL
;	NULL
5	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
Rap	NULL
)	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
as	NULL
indicated	NULL
for	NULL
20	NULL
h.	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
generated	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
specific	NULL
antibodies	NULL
for	NULL
E2F-1	NULL
and	NULL
E2F-4	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
10	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
DNA	NULL
affinity	NULL
precipitations	NULL
were	NULL
performed	NULL
with	NULL
biotinylated	NULL
oligonucleotides	NULL
containing	NULL
EZA	NULL
sequence	NULL
(	NULL
E2A-AP	NULL
)	NULL
,	NULL
with	NULL
a	NULL
mutant	NULL
E2A	NULL
biotinylated	NULL
oligonucleotide	NULL
(	NULL
two	NULL
point	NULL
mutations	NULL
in	NULL
each	NULL
E2F	NULL
binding	NULL
site	NULL
)	NULL
(	NULL
mutant	NULL
EZA-AP	NULL
)	NULL
or	NULL
with	NULL
biotinylated	NULL
oligonucleotides	NULL
containing	NULL
E2A	NULL
sequence	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
10-fold	NULL
excess	NULL
of	NULL
unbiotinylated	NULL
E2F	NULL
binding	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
(	NULL
E2A-AP+comp	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
with	NULL
E2F-1-specific	NULL
antibodies	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
10	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
20	NULL
h.	NULL
Samples	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
DNA	NULL
affinity	NULL
precipitations	NULL
were	NULL
performed	NULL
with	NULL
biotinylated	NULL
oligonucleotides	NULL
containing	NULL
EZA	NULL
sequence	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
with	NULL
E2F-1-specific	NULL
antibodies	NULL
.	NULL

IL2+Rap	NULL
E2F-1	NULL
show	NULL
that	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
the	NULL
macrolide	NULL
on	NULL
p70®°°*	NULL
activity	NULL
are	NULL
sustained	NULL
at	NULL
6	NULL
and	NULL
24	NULL
h	NULL
following	NULL
IL-2	NULL
stimulation	NULL
.	NULL

Hence	NULL
rapamycin	NULL
was	NULL
effective	NULL
at	NULL
blocking	NULL
p70°°*	NULL
signaling	NULL
pathways	NULL
throughout	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
E2F	NULL
functional	NULL
activity	NULL
assays	NULL
.	NULL

Rapamycin	NULL
inhibition	NULL
of	NULL
p70°*	NULL
phosphorylation	NULL
correlates	NULL
with	NULL
an	NULL
inhibition	NULL
of	NULL
activity	NULL
,	NULL
as	NULL
judged	NULL
from	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
using	NULL
408	NULL
ribosomal	NULL
protein	NULL
$	NULL
6	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
the	NULL
rapamycin-resistant	NULL
component	NULL
of	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
is	NULL
not	NULL
due	NULL
to	NULL
ineffectiveness	NULL
of	NULL
the	NULL
drug	NULL
and	NULL
that	NULL
this	NULL
pathway	NULL
must	NULL
bifurcate	NULL
above	NULL
p70°°	NULL
.	NULL

Rapamycin	NULL
regulates	NULL
E2F	NULL
activity	NULL
but	NULL
not	NULL
the	NULL
expression	NULL
or	NULL
DNA	NULL
binding	NULL
of	NULL
E2F	NULL
proteins	NULL
.	NULL

One	NULL
mechanism	NULL
by	NULL
which	NULL
rapamycin	NULL
could	NULL
block	NULL
EZF	NULL
activity	NULL
is	NULL
to	NULL
downregulate	NULL
cellular	NULL
levels	NULL
of	NULL
E2Fs	NULL
.	NULL

However	NULL
,	NULL
Western	NULL
blot	NULL
analyses	NULL
of	NULL
total	NULL
lysates	NULL
from	NULL
Kit225	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
or	NULL
IL-2	NULL
plus	NULL
rapamycin	NULL
showed	NULL
no	NULL
effect	NULL
of	NULL
rapamycin	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
E2F-1	NULL
and	NULL
E2F-4	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
,	NULL
the	NULL
main	NULL
E2Fs	NULL
found	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
.	NULL

To	NULL
measure	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
EZ2F	NULL
DNA	NULL
binding	NULL
,	NULL
biotinylated	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
EZ2F	NULL
binding	NULL
sequence	NULL
in	NULL
EZ2ACAT	NULL
were	NULL
used	NULL
to	NULL
affinity	NULL
purify	NULL
E2F	NULL
complexes	NULL
from	NULL
cells	NULL
activated	NULL
with	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
rapamycin	NULL
.	NULL

E2F-1	NULL
Western	NULL
blot	NULL
analysis	NULL
showed	NULL
that	NULL
E2A	NULL
oligonucleotides	NULL
can	NULL
effectively	NULL
affinity	NULL
purify	NULL
E2Fs	NULL
from	NULL
cell	NULL
lysates	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
;	NULL
E2F-1	NULL
binding	NULL
was	NULL
lost	NULL
when	NULL
an	NULL
oligonucleotide	NULL
with	NULL
two	NULL
point	NULL
mutations	NULL
in	NULL
each	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
E2A	NULL
oligonucleotide	NULL
was	NULL
used	NULL
in	NULL
the	NULL
affinity	NULL
puri-fications	NULL
or	NULL
when	NULL
cell	NULL
lysates	NULL
were	NULL
preincubated	NULL
with	NULL
unbiotinylated	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Figure	NULL
3C	NULL
shows	NULL
that	NULL
pre-treatment	NULL
of	NULL
Kit225	NULL
cells	NULL
with	NULL
rapamycin	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
IL-2	NULL
for	NULL
20	NULL
h	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
E2F	NULL
DNA	NULL
binding	NULL
.	NULL

This	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
12	NULL
[	NULL
-	NULL
]	NULL
Con	NULL
IL-2	NULL
10	NULL
.	NULL

1	NULL
{	NULL
*	NULL
i	NULL
,	NULL
as	NULL
*	NULL
i	NULL
2	NULL
0	NULL
E2ACAT	NULL
E2ACAT	NULL
E2ACAT	NULL
+	NULL
Empty	NULL
_	NULL
+RbA	NULL
(	NULL
204g	NULL
)	NULL
+RbA	NULL
(	NULL
104g	NULL
)	NULL
B	NULL
Total	NULL
E2A	NULL
Lysate	NULL
AP	NULL
I2	NULL
_-	NULL
_+	NULL
-	NULL
+	NULL
LJ	NULL
pRb	NULL
-|	NULL
«	NULL
s	NULL
*	NULL
c	NULL
p130	NULL
112	NULL
0	NULL
20	NULL
5	NULL
2	NULL
1	NULL
0.5	NULL
0.25	NULL
0.125	NULL
0.0625	NULL
Rap	NULL
-	NULL
__+	NULL
_-	NULL
Ok	NULL
O-	NULL
Ok	NULL
-	NULL
h	NULL
-	NULL
¢	NULL
-	NULL
#	NULL
-	NULL
$	NULL
-	NULL
#	NULL
-	NULL
+	NULL
pRb	NULL
IL2	NULL
0	NULL
20	NULL
5	NULL
2	NULL
1	NULL
0.5	NULL
0.25	NULL
0.125	NULL
0.0625	NULL
Rap	NULL
-	NULL
_	NULL
k	NULL
_-	NULL
Ok	NULL
O-	NULL
Oh	NULL
-	NULL
h	NULL
s-	NULL
of	NULL
-	NULL
g	NULL
-	NULL
#	NULL
-	NULL
#	NULL
$	NULL
-	NULL
+	NULL
dw	NULL
sein	NULL
#	NULL
#	NULL
‘	NULL
i	NULL
!	NULL

k	NULL
!	NULL

’	NULL
_._¢3-~-IL2+Rap	NULL
D	NULL
Con	NULL
IL2	NULL
20	NULL
10	NULL
5	NULL
Rb-P	NULL
<	NULL
a	NULL
``	NULL
pBb	NULL
Rp	NULL
TE	NULL
TOP	NULL
ano	NULL
~p130	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Rapamycin	NULL
and	NULL
pocket	NULL
proteins	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
cotransfected	NULL
with	NULL
E2ACAT	NULL
reporter	NULL
with	NULL
a	NULL
mammalian	NULL
expression	NULL
vector	NULL
for	NULL
a	NULL
form	NULL
of	NULL
pRb	NULL
in	NULL
which	NULL
the	NULL
edc2	NULL
phosphorylation	NULL
sites	NULL
had	NULL
been	NULL
mutated	NULL
(	NULL
pRbA	NULL
)	NULL
or	NULL
with	NULL
empty	NULL
vector	NULL
as	NULL
a	NULL
control	NULL
.	NULL

After	NULL
4	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
Con	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

Eighteen	NULL
hours	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
lysed	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
10	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

as	NULL
indicated	NULL
for	NULL
20	NULL
h.	NULL
Samples	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
DNA	NULL
affinity	NULL
precipitations	NULL
(	NULL
AP	NULL
)	NULL
were	NULL
performed	NULL
with	NULL
biotinylated	NULL
oligonucleotides	NULL
containing	NULL
E2A	NULL
sequence	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
with	NULL
specific	NULL
pRb	NULL
and	NULL
p130	NULL
antibodies	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
10°	NULL
per	NULL
ml	NULL
;	NULL
5	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
at	NULL
the	NULL
doses	NULL
indicated	NULL
(	NULL
in	NULL
nanograms	NULL
per	NULL
milliliter	NULL
)	NULL
for	NULL
20	NULL
h.	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
generated	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
by	NULL
using	NULL
specific	NULL
antibodies	NULL
for	NULL
pRb	NULL
and	NULL
p130	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
10	NULL
per	NULL
ml	NULL
;	NULL
5	NULL
ml	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
rapamycin	NULL
as	NULL
indicated	NULL
(	NULL
in	NULL
nanograms	NULL
per	NULL
milliliter	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
20	NULL
h.	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
generated	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

Protein	NULL
was	NULL
detected	NULL
with	NULL
specific	NULL
antibodies	NULL
for	NULL
pRb	NULL
and	NULL
p130	NULL
.	NULL

Con	NULL
,	NULL
control	NULL
.	NULL

suggests	NULL
that	NULL
rapamycin	NULL
inhibits	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
DNA-bound	NULL
E2F	NULL
complexes	NULL
,	NULL
not	NULL
their	NULL
expression	NULL
or	NULL
DNA	NULL
binding	NULL
.	NULL

Rapamycin	NULL
inhibits	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
.	NULL

One	NULL
key	NULL
mechanism	NULL
to	NULL
control	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
is	NULL
the	NULL
formation	NULL
of	NULL
E2F	NULL
pocket	NULL
protein	NULL
complexes	NULL
,	NULL
a	NULL
process	NULL
controlled	NULL
by	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
.	NULL

When	NULL
Kit225	NULL
cells	NULL
are	NULL
transfected	NULL
with	NULL
EZ2ACAT	NULL
and	NULL
an	NULL
Rb	NULL
construct	NULL
(	NULL
pRbA	NULL
)	NULL
in	NULL
which	NULL
the	NULL
p34	NULL
``	NULL
phosphorylation	NULL
sites	NULL
are	NULL
mutated	NULL
(	NULL
13	NULL
)	NULL
,	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
is	NULL
lost	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
quiescent	NULL
T	NULL
lymphocytes	NULL
,	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
the	NULL
pocket	NULL
binding	NULL
proteins	NULL
Rb	NULL
and	NULL
p130	NULL
predominate	NULL
.	NULL

The	NULL
phosphorylation	NULL
of	NULL
pocket	NULL
proteins	NULL
was	NULL
monitored	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
in	NULL
SDS-PAGE	NULL
gels	NULL
.	NULL

In	NULL
these	NULL
biochemical	NULL
analyses	NULL
,	NULL
we	NULL
studied	NULL
p70°	NULL
``	NULL
,	NULL
RAPAMYCIN	NULL
,	NULL
AND	NULL
E2F	NULL
-	NULL
4733	NULL
IL-2	NULL
responses	NULL
in	NULL
Kit225	NULL
cells	NULL
and	NULL
also	NULL
in	NULL
human	NULL
peripheral	NULL
blood-derived	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
data	NULL
from	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
are	NULL
shown	NULL
because	NULL
of	NULL
the	NULL
physiological	NULL
relevance	NULL
of	NULL
these	NULL
cells	NULL
as	NULL
the	NULL
target	NULL
for	NULL
the	NULL
in	NULL
vivo	NULL
actions	NULL
of	NULL
rapamycin	NULL
;	NULL
the	NULL
same	NULL
result	NULL
was	NULL
observed	NULL
in	NULL
Kit225	NULL
cells	NULL
.	NULL

Figure	NULL
4B	NULL
demonstrates	NULL
that	NULL
hyperphosphorylation	NULL
of	NULL
Rb	NULL
and	NULL
p130	NULL
is	NULL
induced	NULL
by	NULL
IL-2	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
their	NULL
reduced	NULL
electrophoretic	NULL
mobilities	NULL
following	NULL
IL-2	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
show	NULL
that	NULL
E2F-DNA	NULL
protein	NULL
complexes	NULL
contain	NULL
only	NULL
the	NULL
fast-migrating	NULL
,	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
the	NULL
pocket	NULL
proteins	NULL
p130	NULL
and	NULL
pRb	NULL
.	NULL

The	NULL
slower	NULL
electrophoretic	NULL
mobility	NULL
forms	NULL
of	NULL
pRb	NULL
and	NULL
p130	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
hyperphosphorylated	NULL
pocket	NULL
proteins	NULL
,	NULL
are	NULL
unable	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
E2F	NULL
complexes	NULL
,	NULL
although	NULL
they	NULL
are	NULL
readily	NULL
detectable	NULL
in	NULL
total	NULL
cell	NULL
lysates	NULL
.	NULL

To	NULL
explore	NULL
whether	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
phosphorylation	NULL
of	NULL
pRb	NULL
and	NULL
p130	NULL
in	NULL
rapamycin-treated	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
are	NULL
for	NULL
peripheral	NULL
blood-derived	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
indistinguishable	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
Kit225	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
a	NULL
range	NULL
of	NULL
concentrations	NULL
of	NULL
IL-2	NULL
.	NULL

For	NULL
each	NULL
dose	NULL
of	NULL
IL-2	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
was	NULL
monitored	NULL
.	NULL

The	NULL
data	NULL
show	NULL
that	NULL
IL-2	NULL
induces	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
pRb	NULL
and	NULL
p130	NULL
at	NULL
cytokine	NULL
concentrations	NULL
coinciding	NULL
with	NULL
those	NULL
that	NULL
induce	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

There	NULL
is	NULL
inhibition	NULL
of	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
both	NULL
Rb	NULL
and	NULL
p130	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
.	NULL

This	NULL
inhibition	NULL
is	NULL
suppressed	NULL
at	NULL
high	NULL
concentrations	NULL
of	NULL
IL-2	NULL
.	NULL

It	NULL
is	NULL
most	NULL
marked	NULL
in	NULL
cells	NULL
activated	NULL
by	NULL
low	NULL
concentrations	NULL
of	NULL
cytokine	NULL
that	NULL
give	NULL
suboptimal	NULL
induction	NULL
of	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

4D	NULL
show	NULL
a	NULL
rapamycin	NULL
dose	NULL
response	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
Rb	NULL
and	NULL
p130	NULL
hyperphosphorylation	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
rapamycin	NULL
are	NULL
seen	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
5	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
,	NULL
and	NULL
increasing	NULL
the	NULL
drug	NULL
dose	NULL
to	NULL
20	NULL
ng/ml	NULL
has	NULL
no	NULL
further	NULL
inhibitory	NULL
effect	NULL
on	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
.	NULL

These	NULL
inhibitory	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
the	NULL
phosphorylation	NULL
of	NULL
pocket	NULL
proteins	NULL
could	NULL
explain	NULL
why	NULL
this	NULL
drug	NULL
can	NULL
antagonize	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
rapamycin	NULL
to	NULL
totally	NULL
suppress	NULL
IL-2-induced	NULL
Rb	NULL
and	NULL
p130	NULL
phosphorylations	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
failure	NULL
of	NULL
rapamycin	NULL
to	NULL
totally	NULL
abrogate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
are	NULL
also	NULL
fully	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
rapamycin	NULL
blocks	NULL
T-cell	NULL
proliferation	NULL
by	NULL
delaying	NULL
G	NULL
;	NULL
transit	NULL
times	NULL
rather	NULL
than	NULL
by	NULL
causing	NULL
an	NULL
absolute	NULL
mitotic	NULL
block	NULL
(	NULL
43	NULL
)	NULL
.	NULL

p70°*	NULL
regulates	NULL
E2Fs	NULL
in	NULL
Kit225	NULL
cells	NULL
.	NULL

IL-2	NULL
activates	NULL
p70°*	NULL
in	NULL
a	NULL
PI	NULL
3-kinase-	NULL
and	NULL
rapamycin-dependent	NULL
pathway	NULL
(	NULL
34	NULL
)	NULL
.	NULL

To	NULL
explore	NULL
the	NULL
role	NULL
of	NULL
p70°®*	NULL
in	NULL
E2F	NULL
regulation	NULL
in	NULL
Kit225	NULL
cells	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
overexpression	NULL
of	NULL
p70®°	NULL
``	NULL
*	NULL
on	NULL
IL-2	NULL
activation	NULL
of	NULL
E2ACAT	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
overexpression	NULL
of	NULL
a	NULL
myc	NULL
epitope-tagged	NULL
wild-type	NULL
p70°°	NULL
>	NULL
raised	NULL
basal	NULL
levels	NULL
of	NULL
EZ2ACAT	NULL
and	NULL
augmented	NULL
the	NULL
effects	NULL
of	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

This	NULL
response	NULL
required	NULL
p70®*	NULL
catalytic	NULL
activity	NULL
,	NULL
as	NULL
it	NULL
was	NULL
not	NULL
seen	NULL
in	NULL
cells	NULL
expressing	NULL
comparable	NULL
levels	NULL
of	NULL
p70°*Q1	NULL
,	NULL
,	NULL
,	NULL
a	NULL
catalytically	NULL
inactive	NULL
variant	NULL
in	NULL
which	NULL
the	NULL
critical	NULL
lysine	NULL
residue	NULL
in	NULL
the	NULL
ATP	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
kinase	NULL
is	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
expression	NULL
of	NULL
wild-type	NULL
p70°®*	NULL
on	NULL
the	NULL
upregulation	NULL
of	NULL
E2ACAT	NULL
activity	NULL
was	NULL
abrogated	NULL
by	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
whereas	NULL
IL-2-E2F	NULL
responses	NULL
were	NULL
only	NULL
50	NULL
%	NULL
inhibited	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
rapamycin-resistant	NULL
pathways	NULL
from	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
bifurcate	NULL
above	NULL
p70®°~	NULL
.	NULL

The	NULL
rapamycin-resistant	NULL
p70°**	NULL
mutant	NULL
,	NULL
p70**D3E-Esso	NULL
,	NULL
regulates	NULL
E2F	NULL
activity	NULL
in	NULL
Kit225	NULL
cells	NULL
.	NULL

is	NULL
a	NULL
mutant	NULL
in	NULL
which	NULL
threonine	NULL
389	NULL
,	NULL
the	NULL
main	NULL
target	NULL
of	NULL
rapamycin-induced	NULL
p70°*	NULL
inactivation	NULL
,	NULL
has	NULL
been	NULL
replaced	NULL
by	NULL
a	NULL
glutamic	NULL
acid	NULL
and	NULL
the	NULL
four	NULL
serine	NULL
or	NULL
threonine	NULL
phosphorylation	NULL
sites	NULL
in	NULL
4734	NULL
BRENNAN	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
[	NULL
-	NULL
]	NULL
Con	NULL
T=	NULL
IL-2	NULL
2	NULL
14	NULL
r	NULL
H	NULL
'	NULL
a	NULL
S	NULL
212	NULL
9	NULL
9	NULL
Ed	NULL
»	NULL
10	NULL
>	NULL
.	NULL

8	NULL
RS	NULL
&	NULL
6	NULL
6	NULL
&	NULL
aa	NULL
a	NULL
U	NULL
AG	NULL
2	NULL
2	NULL
0	NULL
Empty	NULL
S6k	NULL
WT	NULL
S6k	NULL
Q100	NULL
S6K	NULL
#	NULL
»	NULL
Cag	NULL
#	NULL
-	NULL
#	NULL
Vec	NULL
S6kWT	NULL
Sok	NULL
Q100	NULL
B	NULL
m	NULL
-	NULL
Wild	NULL
type	NULL
S6k	NULL
14	NULL
O	NULL
Empty	NULL
vector	NULL
12	NULL
ad	NULL
H	NULL
~	NULL
2	NULL
§10	NULL
3.9	NULL
a	NULL
E	NULL
8	NULL
&	NULL
6	NULL
U	NULL
3	NULL
dy	NULL
4	NULL
HS	NULL
0	NULL
5	NULL
10	NULL
.	NULL

_	NULL
4A§	NULL
20	NULL
Rapamycin	NULL
concentration	NULL
(	NULL
ng/ml	NULL
)	NULL
FIG	NULL
.	NULL

5.	NULL
p70®*	NULL
increases	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
(	NULL
Top	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
and	NULL
with	NULL
10	NULL
pg	NULL
each	NULL
of	NULL
either	NULL
empty	NULL
vector	NULL
,	NULL
wild-type	NULL
p70®*	NULL
(	NULL
§S6k	NULL
WT	NULL
)	NULL
,	NULL
or	NULL
p70®	NULL
``	NULL
``	NULL
Q10p	NULL
(	NULL
Q100	NULL
)	NULL
(	NULL
kinase-dead	NULL
S6k	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
for	NULL
4	NULL
h	NULL
and	NULL
were	NULL
either	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
IL-2/ml	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
or	NULL
left	NULL
unstimulated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
(	NULL
Con	NULL
)	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
In	NULL
parallel	NULL
experiments	NULL
,	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
myc	NULL
epitope-tagged	NULL
S6k	NULL
constructs	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
overnight	NULL
and	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
the	NULL
expressed	NULL
S6k	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
myc	NULL
tag-specific	NULL
antibody	NULL
and	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Transfected	NULL
myc-tagged	NULL
S6k	NULL
was	NULL
detected	NULL
with	NULL
myc	NULL
tag-specific	NULL
antibody	NULL
(	NULL
9E10	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
pg	NULL
)	NULL
and	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
wild-type	NULL
p70®	NULL
or	NULL
empty	NULL
vector	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
for	NULL
4	NULL
h.	NULL
They	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
rapamycin	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

the	NULL
autoinhibitory	NULL
domain	NULL
have	NULL
been	NULL
changed	NULL
to	NULL
either	NULL
aspar-tic	NULL
or	NULL
glutamic	NULL
acid	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
mutant	NULL
shows	NULL
rapamycin-insensitive	NULL
catalytic	NULL
activity	NULL
in	NULL
kidney	NULL
293	NULL
cells	NULL
(	NULL
19	NULL
,	NULL
46	NULL
)	NULL
.	NULL

It	NULL
retains	NULL
20	NULL
%	NULL
of	NULL
serum-stimulated	NULL
activity	NULL
compared	NULL
to	NULL
the	NULL
2	NULL
%	NULL
residual	NULL
S6	NULL
kinase	NULL
activity	NULL
seen	NULL
in	NULL
wild-type	NULL
p70®°°*	NULL
when	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
20	NULL
nM	NULL
rapamycin	NULL
(	NULL
equivalent	NULL
to	NULL
18.3	NULL
ng/ml	NULL
)	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
retains	NULL
50	NULL
%	NULL
of	NULL
its	NULL
catalytic	NULL
activity	NULL
in	NULL
rapamycin-	NULL
and	NULL
insulin-treated	NULL
293	NULL
cells	NULL
compared	NULL
to	NULL
the	NULL
5	NULL
%	NULL
residual	NULL
activity	NULL
present	NULL
in	NULL
wild-type	NULL
enzyme	NULL
isolated	NULL
from	NULL
rapamycin-	NULL
and	NULL
insulin-treated	NULL
cells	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
rapamycin	NULL
sensitivity	NULL
of	NULL
catalytic	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
has	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

Figure	NULL
6A	NULL
shows	NULL
the	NULL
kinase	NULL
activity	NULL
,	NULL
relative	NULL
quantitation	NULL
,	NULL
and	NULL
expression	NULL
in	NULL
IL-2-activated	NULL
Kit225	NULL
cells	NULL
of	NULL
wild-type	NULL
p70°°®	NULL
,	NULL
and	NULL
p70®	NULL
``	NULL
Qinp	NULL
.	NULL

Ro-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
Sok	NULL
WT	NULL
S6kE389D	NULL
,	NULL
E	NULL
-	NULL
S6k	NULL
Unt	NULL
Q100	NULL
Rap	NULL
-	NULL
#	NULL
4+	NULL
=-	NULL
#	NULL
$	NULL
0	NULL
-o-Kinase	NULL
activity	NULL
‘	NULL
v	NULL
*-Relative	NULL
[	NULL
100	NULL
7	NULL
s	NULL
100	NULL
63	NULL
61	NULL
_-	NULL
Quantitation	NULL
Expression	NULL
<	NULL
a6	NULL
Whip	NULL
v	NULL
4	NULL
vom	NULL
wae	NULL
sas	NULL
®	NULL
-	NULL
S6kE389D	NULL
,	NULL
E	NULL
B	NULL
C	NULL
0	NULL
-	NULL
S6k	NULL
WT	NULL
2	NULL
100	NULL
o	NULL
a	NULL
2	NULL
so	NULL
C	NULL
E	NULL
B	NULL
60	NULL
o	NULL
o	NULL
&	NULL
40	NULL
5	NULL
'	NULL
>	NULL
20	NULL
S	NULL
Ed	NULL
0	NULL
*	NULL
+	NULL
I	NULL
¥	NULL
=o	NULL
a	NULL
1	NULL
10	NULL
un	NULL
Rapamycin	NULL
concentration	NULL
(	NULL
ng/ml	NULL
)	NULL
FIG	NULL
.	NULL

6.	NULL
is	NULL
rapamycin	NULL
resistant	NULL
in	NULL
T-cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
30	NULL
mg	NULL
each	NULL
of	NULL
empty	NULL
vector	NULL
,	NULL
wild-type	NULL
p70®*	NULL
(	NULL
S6k	NULL
WT	NULL
)	NULL
,	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
p70®*	NULL
``	NULL
*D	NULL
;	NULL
E-Ezgo	NULL
,	NULL
Or	NULL
the	NULL
kinase-dead	NULL
mutant	NULL
p70®*Q19	NULL
,	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
overnight	NULL
and	NULL
treated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

.	NULL

Cells	NULL
were	NULL
lysed	NULL
,	NULL
the	NULL
expressed	NULL
S6k	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
myc	NULL
tag-specific	NULL
antibody	NULL
,	NULL
and	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

S6	NULL
substrate	NULL
phosphorylation	NULL
for	NULL
S6	NULL
kinase	NULL
assays	NULL
was	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
(	NULL
top	NULL
)	NULL
,	NULL
and	NULL
expression	NULL
was	NULL
measured	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

(	NULL
Center	NULL
)	NULL
Incorporated	NULL
radioactivity	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
PhosphorImager	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
relative	NULL
to	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
rapamycin	NULL
,	NULL
taken	NULL
as	NULL
100	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
30	NULL
ug	NULL
each	NULL
of	NULL
empty	NULL
vector	NULL
,	NULL
wild-type	NULL
p70®*	NULL
,	NULL
or	NULL
p70	NULL
``	NULL
``	NULL
Q1pp	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
overnight	NULL
and	NULL
treated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
rapamycin	NULL
at	NULL
the	NULL
doses	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
,	NULL
the	NULL
expressed	NULL
S6k	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
myc	NULL
tag-specific	NULL
antibody	NULL
,	NULL
and	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

S6	NULL
substrate-incorporated	NULL
radioactivity	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
PhosphorImager	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
relative	NULL
to	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
rapamycin	NULL
,	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
.	NULL

bust	NULL
$	NULL
6	NULL
kinase	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
immunoprecipitates	NULL
of	NULL
both	NULL
wild-type	NULL
p70°	NULL
``	NULL
*	NULL
and	NULL
p70®°*D	NULL
;	NULL
,	NULL
E-Ess	NULL
,	NULL
,	NULL
whereas	NULL
p70®	NULL
``	NULL
Q100	NULL
was	NULL
catalytically	NULL
inactive	NULL
.	NULL

When	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
or	NULL
20	NULL
ng	NULL
of	NULL
rapamycin/ml	NULL
for	NULL
20	NULL
min	NULL
,	NULL
p70°°*D	NULL
;	NULL
E-Ess	NULL
,	NULL
retained	NULL
more	NULL
than	NULL
60	NULL
%	NULL
catalytic	NULL
activity	NULL
in	NULL
rapamycin-treated	NULL
cells	NULL
,	NULL
compared	NULL
to	NULL
the	NULL
5	NULL
to	NULL
10	NULL
%	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
enzyme	NULL
under	NULL
similar	NULL
conditions	NULL
.	NULL

The	NULL
clear	NULL
resistance	NULL
to	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
p70°°*D	NULL
;	NULL
E-Esg	NULL
,	NULL
is	NULL
also	NULL
shown	NULL
by	NULL
a	NULL
comparison	NULL
of	NULL
the	NULL
rapamycin	NULL
dose	NULL
response	NULL
for	NULL
inhibition	NULL
of	NULL
p70°°*D	NULL
,	NULL
E-E	NULL
;	NULL
;	NULL
,	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
kinase	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

If	NULL
p70°°*	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
rapamycin-sensitive	NULL
responses	NULL
that	NULL
regulate	NULL
E2Fs	NULL
,	NULL
then	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70®*	NULL
should	NULL
rescue	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
rapamycin-treated	NULL
cells	NULL
.	NULL

Figure	NULL
7A	NULL
shows	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
rapamycin-resistant	NULL
S6	NULL
kinase	NULL
mutant	NULL
raises	NULL
basal	NULL
E2ACAT	NULL
activity	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
E2ACAT	NULL
stimulated	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70®*	NULL
was	NULL
strikingly	NULL
less	NULL
sensitive	NULL
to	NULL
rapamycin	NULL
treatment	NULL
than	NULL
that	NULL
for	NULL
the	NULL
wild-type	NULL
p70°*	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
E2F	NULL
response	NULL
to	NULL
still	NULL
retains	NULL
some	NULL
sensitivity	NULL
to	NULL
rapamycin	NULL
treatment	NULL
,	NULL
but	NULL
this	NULL
is	NULL
expected	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
®	NULL
S6k	NULL
WT	NULL
O	NULL
S6k	NULL
WT	NULL
+	NULL
Rap	NULL
m	NULL
S6kE389D	NULL
,	NULL
E	NULL
O	NULL
S6kE389D	NULL
,	NULL
E	NULL
+	NULL
Rap	NULL
A	NULL
20	NULL
r	NULL
E2ACAT	NULL
activity	NULL
(	NULL
%	NULL
acetylation	NULL
)	NULL
10	NULL
15	NULL
DNA	NULL
concentration	NULL
(	NULL
ug/ml	NULL
)	NULL
B	NULL
120	NULL
m	NULL
S6kE389D	NULL
,	NULL
E	NULL
e	NULL
S6k	NULL
WT	NULL
E2ACAT	NULL
activity	NULL
(	NULL
%	NULL
maximum	NULL
)	NULL
Rapamycin	NULL
concentration	NULL
(	NULL
ng/ml	NULL
)	NULL
FIG	NULL
.	NULL

7.	NULL
p70®*D	NULL
;	NULL
E-E4e	NULL
,	NULL
rescues	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
pg	NULL
)	NULL
and	NULL
with	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
p70®*	NULL
or	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
(	NULL
p70®*D3E-Eseg	NULL
)	NULL
at	NULL
various	NULL
concentrations	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
for	NULL
4	NULL
h	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
rapamycin	NULL
(	NULL
Rap	NULL
)	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
E2ACAT	NULL
(	NULL
20	NULL
pg	NULL
)	NULL
and	NULL
with	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
p70®	NULL
or	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
Cells	NULL
were	NULL
left	NULL
for	NULL
4	NULL
h.	NULL
They	NULL
were	NULL
then	NULL
pretreated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
rapamycin	NULL
and	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

.	NULL

After	NULL
18	NULL
h	NULL
,	NULL
samples	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

given	NULL
that	NULL
this	NULL
mutant	NULL
is	NULL
not	NULL
completely	NULL
rapamycin	NULL
resistant	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
also	NULL
potentiated	NULL
IL-2	NULL
induction	NULL
of	NULL
EZ2F	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
conferred	NULL
a	NULL
significant	NULL
degree	NULL
of	NULL
rapamycin	NULL
resistance	NULL
to	NULL
the	NULL
E2F	NULL
regulation	NULL
by	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

In	NULL
data	NULL
averaged	NULL
from	NULL
seven	NULL
experiments	NULL
,	NULL
rapamycin	NULL
caused	NULL
approximately	NULL
55	NULL
to	NULL
60	NULL
%	NULL
inhibition	NULL
of	NULL
the	NULL
EZF	NULL
responses	NULL
to	NULL
IL-2	NULL
in	NULL
cells	NULL
expressing	NULL
wild-type	NULL
p70®	NULL
``	NULL
,	NULL
whereas	NULL
in	NULL
cells	NULL
expressing	NULL
the	NULL
p70°®°*D	NULL
,	NULL
E-E	NULL
;	NULL
,	NULL
,	NULL
mutant	NULL
,	NULL
the	NULL
inhibition	NULL
was	NULL
only	NULL
20	NULL
to	NULL
25	NULL
%	NULL
.	NULL

Expression	NULL
of	NULL
can	NULL
thus	NULL
rescue	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
in	NULL
rapamycin-treated	NULL
cells	NULL
.	NULL

It	NULL
does	NULL
not	NULL
fully	NULL
rescue	NULL
the	NULL
E2F	NULL
response	NULL
,	NULL
but	NULL
this	NULL
is	NULL
explained	NULL
by	NULL
the	NULL
partial	NULL
rapamycin	NULL
sensitivity	NULL
of	NULL
the	NULL
catalytic	NULL
function	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
experiments	NULL
with	NULL
p70°*	NULL
mutants	NULL
indicate	NULL
that	NULL
p70°*	NULL
is	NULL
the	NULL
intermediate	NULL
of	NULL
the	NULL
rapamycin-sensitive	NULL
pathway	NULL
from	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
to	NULL
E2Fs	NULL
.	NULL

p70°	NULL
``	NULL
,	NULL
RAPAMYCIN	NULL
,	NULL
AND	NULL
E2F	NULL
|-	NULL
4735	NULL
n	NULL
o	NULL
50	NULL
7	NULL
m	NULL
n	NULL
45	NULL
+	NULL
m	NULL
3	NULL
t	NULL
40	NULL
+	NULL
g	NULL
85	NULL
1	NULL
é	NULL
35s	NULL
‘	NULL
&	NULL
so	NULL
&	NULL
so	NULL
a	NULL
25	NULL
1	NULL
g	NULL
25	NULL
E	NULL
29	NULL
1	NULL
3	NULL
20	NULL
1	NULL
5	NULL
t	NULL
m	NULL
15	NULL
‘	NULL
10	NULL
+	NULL
*	NULL
10	NULL
‘	NULL
5	NULL
T	NULL
5	NULL
°	NULL
IL2	NULL
IL2	NULL
IL2	NULL
IL2	NULL
IL2	NULL
IL2	NULL
+Rap	NULL
+Rap	NULL
+Rap	NULL
S6k	NULL
WT	NULL
-	NULL
Untransfected	NULL
FIG	NULL
.	NULL

8.	NULL
p70°*D	NULL
;	NULL
E-E4e	NULL
,	NULL
does	NULL
not	NULL
rescue	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
T-cell	NULL
cycle	NULL
entry	NULL
.	NULL

Quiescent	NULL
Kit225	NULL
cells	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
p70®*	NULL
or	NULL
p70®*D	NULL
,	NULL
E-E4	NULL
&	NULL
,	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
overnight	NULL
.	NULL

They	NULL
were	NULL
then	NULL
pretreated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
rapamycin	NULL
(	NULL
Rap	NULL
)	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

After	NULL
8	NULL
h	NULL
,	NULL
10	NULL
M	NULL
BrdU	NULL
was	NULL
added	NULL
to	NULL
samples	NULL
.	NULL

Twelve	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
BrdU	NULL
incorporation	NULL
and	NULL
protein	NULL
expression	NULL
by	NULL
FACS	NULL
.	NULL

The	NULL
rapamycin-resistant	NULL
p70°**	NULL
mutant	NULL
,	NULL
p70**D3E-Esso	NULL
,	NULL
does	NULL
not	NULL
rescue	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
cell	NULL
cycle	NULL
entry	NULL
.	NULL

A	NULL
rapamycin-resistant	NULL
was	NULL
sufficient	NULL
to	NULL
rescue	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
rapamycin-treated	NULL
T	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
even	NULL
though	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
EZFs	NULL
is	NULL
required	NULL
,	NULL
it	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
T-cell	NULL
cycle	NULL
progression	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
mTOR	NULL
has	NULL
other	NULL
downstream	NULL
effectors	NULL
distinct	NULL
from	NULL
p70®*	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
whether	NULL
expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
was	NULL
sufficient	NULL
to	NULL
restore	NULL
T-cell	NULL
cycle	NULL
progression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
or	NULL
whether	NULL
other	NULL
rapamycin-sensitive	NULL
targets	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
IL-2-mediated	NULL
response	NULL
.	NULL

To	NULL
perform	NULL
this	NULL
experiment	NULL
,	NULL
we	NULL
transfected	NULL
cells	NULL
with	NULL
mye	NULL
epitope-tagged	NULL
wild-type	NULL
p70°®*	NULL
and	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
p70°®°*D	NULL
,	NULL
E-E	NULL
;	NULL
;	NULL
,	NULL
.	NULL

We	NULL
then	NULL
labelled	NULL
the	NULL
cells	NULL
with	NULL
BrdU	NULL
and	NULL
used	NULL
antibodies	NULL
to	NULL
detect	NULL
p70®*	NULL
expression	NULL
and	NULL
BrdU	NULL
incorporation	NULL
.	NULL

The	NULL
results	NULL
show	NULL
BrdU	NULL
incorporation	NULL
in	NULL
Kit225	NULL
cells	NULL
expressing	NULL
either	NULL
wild-type	NULL
p70°*	NULL
or	NULL
the	NULL
rapamycin-resistant	NULL
mutant	NULL
p70®*D	NULL
,	NULL
E-Esg	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
wild-type	NULL
p70°°	NULL
,	NULL
rapamycin	NULL
had	NULL
a	NULL
dramatic	NULL
effect	NULL
on	NULL
DNA	NULL
incorporation	NULL
,	NULL
lowering	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
entering	NULL
the	NULL
cell	NULL
cycle	NULL
from	NULL
about	NULL
40	NULL
%	NULL
to	NULL
less	NULL
than	NULL
20	NULL
%	NULL
of	NULL
cells	NULL
.	NULL

In	NULL
cells	NULL
expressing	NULL
DNA	NULL
synthesis	NULL
was	NULL
inhibited	NULL
to	NULL
an	NULL
equivalent	NULL
extent	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
mTOR	NULL
has	NULL
other	NULL
downstream	NULL
effector	NULL
targets	NULL
involved	NULL
in	NULL
T-cell	NULL
cycle	NULL
progression	NULL
in	NULL
addition	NULL
to	NULL
p70°°	NULL
.	NULL

DISCUSSION	NULL
In	NULL
T	NULL
lymphocytes	NULL
,	NULL
the	NULL
cytokine	NULL
IL-2	NULL
controls	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2Fs	NULL
,	NULL
a	NULL
critical	NULL
cell	NULL
cycle	NULL
event	NULL
.	NULL

IL-2	NULL
activation	NULL
of	NULL
E2Fs	NULL
is	NULL
controlled	NULL
by	NULL
PI	NULL
3-kinase	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
one	NULL
objective	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
explore	NULL
the	NULL
PI	NULL
3-kinase	NULL
signaling	NULL
pathways	NULL
involved	NULL
in	NULL
E2F	NULL
regulation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
PI	NULL
3-kinase	NULL
regulates	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
ribosomal	NULL
S6	NULL
kinase	NULL
,	NULL
p70®	NULL
``	NULL
*	NULL
,	NULL
by	NULL
a	NULL
rapamycin-sensitive	NULL
mechanism	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
present	NULL
results	NULL
show	NULL
that	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
regulation	NULL
of	NULL
E2Fs	NULL
is	NULL
sensitive	NULL
to	NULL
inhibition	NULL
with	NULL
rapamycin	NULL
.	NULL

Rapamycin	NULL
inhibits	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
p70°®	NULL
``	NULL
®	NULL
,	NULL
and	NULL
4736	NULL
BRENNAN	NULL
ET	NULL
AL	NULL
.	NULL

M	NULL
4EBPI	NULL
5°-TOP	NULL
dependent	NULL
Cap	NULL
dependent	NULL
translation	NULL
translation	NULL
f	NULL
initiation	NULL
p7086k	NULL
Y	NULL
cyclin/edk	NULL
activity	NULL
Transactivation	NULL
W+	NULL
G1/S	NULL
phase	NULL
progression	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

IL-2	NULL
signaling	NULL
to	NULL
E2F	NULL
and	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Role	NULL
of	NULL
p70®*	NULL
in	NULL
E2F	NULL
transactivation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
model	NULL
places	NULL
p70®*	NULL
upstream	NULL
of	NULL
translation	NULL
events	NULL
leading	NULL
to	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
but	NULL
demonstrates	NULL
that	NULL
other	NULL
rapamycin-sensitive	NULL
signals	NULL
are	NULL
required	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

the	NULL
inhibitory	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
can	NULL
be	NULL
rescued	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
S6kinase	NULL
.	NULL

However	NULL
,	NULL
a	NULL
rapamycin-resistant	NULL
p70°	NULL
``	NULL
*	NULL
mutant	NULL
does	NULL
not	NULL
rescue	NULL
rapamycin	NULL
inhibition	NULL
of	NULL
T-cell	NULL
cycle	NULL
entry	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
IL-2-PI	NULL
3-kinase	NULL
and	NULL
rapamycin	NULL
pathways	NULL
interact	NULL
centrally	NULL
at	NULL
p70°°®	NULL
,	NULL
leading	NULL
to	NULL
EZF	NULL
transcriptional	NULL
activity	NULL
,	NULL
but	NULL
that	NULL
other	NULL
pathways	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
entry	NULL
.	NULL

We	NULL
have	NULL
illustrated	NULL
these	NULL
concepts	NULL
schematically	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
.	NULL

Rapamycin	NULL
is	NULL
an	NULL
immunosuppressant	NULL
because	NULL
it	NULL
prolongs	NULL
G	NULL
;	NULL
transit	NULL
times	NULL
in	NULL
T	NULL
lymphocytes	NULL
,	NULL
thereby	NULL
inhibiting	NULL
T-cell	NULL
clonal	NULL
expansion	NULL
.	NULL

EZF	NULL
transcriptional	NULL
activity	NULL
is	NULL
a	NULL
rate-limiting	NULL
step	NULL
for	NULL
mitosis	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
any	NULL
influence	NULL
of	NULL
rapamycin	NULL
on	NULL
this	NULL
process	NULL
would	NULL
have	NULL
an	NULL
impact	NULL
on	NULL
T-cell	NULL
cycle	NULL
G	NULL
,	NULL
progression	NULL
and	NULL
would	NULL
explain	NULL
the	NULL
ability	NULL
of	NULL
this	NULL
drug	NULL
to	NULL
markedly	NULL
prolong	NULL
G	NULL
;	NULL
transit	NULL
time	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
present	NULL
results	NULL
thus	NULL
provide	NULL
valuable	NULL
insights	NULL
about	NULL
the	NULL
cell	NULL
cycle	NULL
targets	NULL
for	NULL
the	NULL
action	NULL
of	NULL
rapamycin	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
rapamycin	NULL
to	NULL
suppress	NULL
E2F	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
correlates	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
rapamycin	NULL
to	NULL
inhibit	NULL
the	NULL
accumulation	NULL
of	NULL
phosphorylated	NULL
pocket	NULL
proteins	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
,	NULL
but	NULL
the	NULL
results	NULL
have	NULL
been	NULL
discrepant	NULL
(	NULL
9	NULL
,	NULL
14	NULL
)	NULL
.	NULL

There	NULL
have	NULL
been	NULL
no	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

previous	NULL
reports	NULL
about	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
IL-2-regu-lated	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
even	NULL
though	NULL
these	NULL
cells	NULL
are	NULL
the	NULL
pharmacologically	NULL
relevant	NULL
target	NULL
for	NULL
rapamycin	NULL
.	NULL

Herein	NULL
we	NULL
show	NULL
that	NULL
rapamycin	NULL
inhibits	NULL
IL-2-induced	NULL
hyperphosphorylation	NULL
of	NULL
pRb	NULL
and	NULL
p130	NULL
in	NULL
Kit225	NULL
and	NULL
normal	NULL
human	NULL
peripheral	NULL
blood-derived	NULL
T	NULL
cells	NULL
.	NULL

Rapamycin	NULL
does	NULL
not	NULL
totally	NULL
ablate	NULL
the	NULL
generation	NULL
of	NULL
hyperphosphorylated	NULL
Rb	NULL
and	NULL
p130	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
the	NULL
present	NULL
results	NULL
show	NULL
that	NULL
there	NULL
is	NULL
a	NULL
significant	NULL
accumulation	NULL
of	NULL
hypophosphorylated	NULL
pocket	NULL
proteins	NULL
in	NULL
rapamycin-treated	NULL
T	NULL
cells	NULL
that	NULL
would	NULL
translate	NULL
into	NULL
an	NULL
inhibition	NULL
of	NULL
E2F	NULL
activity	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
rapamycin	NULL
is	NULL
most	NULL
striking	NULL
at	NULL
limiting	NULL
concentrations	NULL
of	NULL
cytokine	NULL
,	NULL
as	NULL
seen	NULL
in	NULL
the	NULL
IL-2	NULL
dose	NULL
response	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
pRb	NULL
and	NULL
p130	NULL
phosphorylation	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
rapamycin	NULL
regulates	NULL
threshold	NULL
responses	NULL
rather	NULL
than	NULL
totally	NULL
ablating	NULL
them	NULL
might	NULL
explain	NULL
the	NULL
discrepancies	NULL
in	NULL
the	NULL
literature	NULL
regarding	NULL
the	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
pocket	NULL
protein	NULL
phosphorylation	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
equally	NULL
possible	NULL
that	NULL
rapamycin	NULL
has	NULL
different	NULL
modes	NULL
of	NULL
action	NULL
in	NULL
controlling	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

Rapamycin	NULL
controls	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
pathways	NULL
that	NULL
bifurcate	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mTOR	NULL
:	NULL
the	NULL
activation	NULL
of	NULL
p70°°*	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
phosphorylation	NULL
of	NULL
4EBP1	NULL
(	NULL
44	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
involvement	NULL
of	NULL
in	NULL
E2F	NULL
regulation	NULL
,	NULL
we	NULL
looked	NULL
at	NULL
the	NULL
effects	NULL
of	NULL
expressing	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70°°*	NULL
on	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
.	NULL

The	NULL
rationale	NULL
for	NULL
these	NULL
experiments	NULL
is	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70®~	NULL
should	NULL
rescue	NULL
EZF	NULL
transcriptional	NULL
activity	NULL
in	NULL
rapamycin-treated	NULL
cells	NULL
if	NULL
p70®*	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
rapamycin-sensitive	NULL
responses	NULL
that	NULL
regulate	NULL
E2Fs	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
overexpression	NULL
of	NULL
wild-type	NULL
raises	NULL
basal	NULL
levels	NULL
of	NULL
E2F	NULL
activity	NULL
and	NULL
potentiates	NULL
E2F	NULL
responses	NULL
to	NULL
IL-2	NULL
.	NULL

Moreover	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
of	NULL
p70°°	NULL
%	NULL
,	NULL
confers	NULL
rapamycin	NULL
resistance	NULL
on	NULL
the	NULL
E2F	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
p70°	NULL
``	NULL
is	NULL
an	NULL
important	NULL
cellular	NULL
target	NULL
for	NULL
the	NULL
action	NULL
of	NULL
rapamycin	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
reveal	NULL
that	NULL
p70°*	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
regulation	NULL
of	NULL
T-cell	NULL
cycle	NULL
progres-sion	NULL
,	NULL
acting	NULL
to	NULL
link	NULL
PI	NULL
3-kinase	NULL
and	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
.	NULL

The	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
p70°*	NULL
on	NULL
EZF	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
indirect	NULL
,	NULL
because	NULL
p70°*	NULL
is	NULL
thought	NULL
to	NULL
have	NULL
a	NULL
single	NULL
cellular	NULL
substrate	NULL
,	NULL
ribosomal	NULL
protein	NULL
S6	NULL
.	NULL

By	NULL
controlling	NULL
$	NULL
6	NULL
phosphorylation	NULL
,	NULL
p70°°*	NULL
regulates	NULL
the	NULL
translation	NULL
of	NULL
an	NULL
essential	NULL
subset	NULL
of	NULL
mRNAs	NULL
that	NULL
contain	NULL
an	NULL
oligopyrimidine	NULL
tract	NULL
at	NULL
their	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
19	NULL
)	NULL
.	NULL

These	NULL
RNAs	NULL
must	NULL
include	NULL
molecules	NULL
that	NULL
can	NULL
regulate	NULL
E2Fs	NULL
.	NULL

In	NULL
preliminary	NULL
experiments	NULL
we	NULL
observed	NULL
that	NULL
rapamycin	NULL
prevents	NULL
IL-2	NULL
induction	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
(	NULL
unpublished	NULL
observation	NULL
)	NULL
.	NULL

These	NULL
D-type	NULL
cyclins	NULL
form	NULL
complexes	NULL
with	NULL
the	NULL
kinases	NULL
edk4	NULL
or	NULL
edk6	NULL
,	NULL
which	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
phosphorylation	NULL
of	NULL
pocket	NULL
proteins	NULL
.	NULL

Accordingly	NULL
,	NULL
one	NULL
prediction	NULL
is	NULL
that	NULL
controls	NULL
E2F	NULL
activity	NULL
via	NULL
regulation	NULL
of	NULL
D-type	NULL
cyclins	NULL
.	NULL

The	NULL
present	NULL
study	NULL
has	NULL
focused	NULL
on	NULL
characterization	NULL
of	NULL
the	NULL
rapamycin-sensitive	NULL
molecules	NULL
involved	NULL
in	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
activation	NULL
of	NULL
E2F	NULL
because	NULL
this	NULL
is	NULL
an	NULL
important	NULL
control	NULL
point	NULL
for	NULL
T-cell	NULL
cycle	NULL
progression	NULL
.	NULL

p70°*	NULL
mediates	NULL
rapamycin	NULL
effects	NULL
on	NULL
E2Fs	NULL
,	NULL
but	NULL
additional	NULL
rapamycin-controlled	NULL
pathways	NULL
are	NULL
clearly	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
entry	NULL
.	NULL

These	NULL
could	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
other	NULL
well-characterized	NULL
target	NULL
for	NULL
rapamycin	NULL
,	NULL
4EBP1	NULL
,	NULL
which	NULL
,	NULL
when	NULL
phosphorylated	NULL
by	NULL
mTOR	NULL
(	NULL
7	NULL
)	NULL
,	NULL
is	NULL
released	NULL
from	NULL
eIF4E	NULL
,	NULL
allowing	NULL
formation	NULL
of	NULL
the	NULL
productive	NULL
mRNA	NULL
cap	NULL
binding	NULL
complex	NULL
critical	NULL
for	NULL
mRNA	NULL
translation	NULL
.	NULL

There	NULL
is	NULL
no	NULL
discrepancy	NULL
between	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
rapamycin-resistant	NULL
p70°~	NULL
mutant	NULL
to	NULL
rescue	NULL
rapamycin-suppressed	NULL
E2F	NULL
activity	NULL
and	NULL
its	NULL
inability	NULL
to	NULL
restore	NULL
T-cell	NULL
cycle	NULL
entry	NULL
in	NULL
rapamycin-treated	NULL
cells	NULL
because	NULL
the	NULL
activation	NULL
of	NULL
E2Fs	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
T-cell	NULL
cycle	NULL
progression	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Cell	NULL
cycle	NULL
control	NULL
in	NULL
mammalian	NULL
cells	NULL
is	NULL
a	NULL
complicated	NULL
process	NULL
involving	NULL
integration	NULL
of	NULL
a	NULL
network	NULL
of	NULL
ra	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
pamycin-sensitive	NULL
and	NULL
-insensitive	NULL
signaling	NULL
pathways	NULL
.	NULL

There	NULL
are	NULL
multiple	NULL
,	NULL
diverse	NULL
rapamycin-insensitive	NULL
pathways	NULL
controlling	NULL
T-cell	NULL
cycle	NULL
progression	NULL
.	NULL

The	NULL
present	NULL
results	NULL
reveal	NULL
that	NULL
there	NULL
is	NULL
similar	NULL
complexity	NULL
to	NULL
the	NULL
rapamycin-controlled	NULL
events	NULL
important	NULL
for	NULL
T-cell	NULL
proliferation	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
present	NULL
study	NULL
brings	NULL
together	NULL
the	NULL
biochemical	NULL
processes	NULL
linking	NULL
the	NULL
IL-2	NULL
receptor	NULL
to	NULL
the	NULL
cell	NULL
cycle	NULL
with	NULL
the	NULL
study	NULL
of	NULL
the	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
rapamycin	NULL
,	NULL
an	NULL
important	NULL
immunosuppressant	NULL
.	NULL

Rapamycin	NULL
inhibits	NULL
T-cell	NULL
proliferation	NULL
,	NULL
and	NULL
it	NULL
is	NULL
accordingly	NULL
important	NULL
to	NULL
understand	NULL
the	NULL
biochemical	NULL
events	NULL
required	NULL
for	NULL
its	NULL
mode	NULL
of	NULL
action	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

We	NULL
show	NULL
that	NULL
targets	NULL
for	NULL
the	NULL
action	NULL
of	NULL
rapamycin	NULL
in	NULL
T	NULL
cells	NULL
are	NULL
signaling	NULL
pathways	NULL
that	NULL
regulate	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

Rapamycin	NULL
completely	NULL
ablates	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
and	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
can	NULL
be	NULL
rescued	NULL
by	NULL
a	NULL
rapamycin-resistant	NULL
mutant	NULL
,	NULL
suggesting	NULL
that	NULL
IL-2-PI	NULL
3-kinase	NULL
and	NULL
rapamycin	NULL
pathways	NULL
interact	NULL
centrally	NULL
at	NULL
p70®°®	NULL
,	NULL
leading	NULL
to	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
rapamycin	NULL
on	NULL
E2F	NULL
activity	NULL
reveal	NULL
a	NULL
molecular	NULL
mechanism	NULL
for	NULL
the	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
rapamycin	NULL
.	NULL

They	NULL
also	NULL
reveal	NULL
a	NULL
role	NULL
for	NULL
p70®*	NULL
as	NULL
a	NULL
mediator	NULL
of	NULL
IL-2	NULL
and	NULL
PI	NULL
3-kinase	NULL
activation	NULL
of	NULL
E2F	NULL
,	NULL
a	NULL
key	NULL
event	NULL
in	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Human	NULL
Frontiers	NULL
Science	NULL
Program	NULL
(	NULL
grant	NULL
RG	NULL
445/95	NULL
)	NULL
,	NULL
EC	NULL
HCM	NULL
Network	NULL
CHRX-CT94-0537	NULL
,	NULL
and	NULL
the	NULL
Imperial	NULL
Cancer	NULL
Research	NULL
Fund	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Beadling	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Guschin	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Witthuhn	NULL
,	NULL
A.	NULL
Ziemiecki	NULL
,	NULL
J.	NULL
N.	NULL
Ihle	NULL
,	NULL
I.	NULL
M.	NULL
Kerr	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
JAK	NULL
kinases	NULL
and	NULL
STAT	NULL
proteins	NULL
by	NULL
interleukin-2	NULL
and	NULL
interferon-	NULL
«	NULL
,	NULL
but	NULL
not	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
,	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5605-5615	NULL
.	NULL

2	NULL
.	NULL

Beadling	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Ng	NULL
,	NULL
J.	NULL
W.	NULL
Babbage	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1996	NULL
.	NULL

Interleukin-2	NULL
activation	NULL
of	NULL
STATS	NULL
requires	NULL
the	NULL
convergent	NULL
action	NULL
of	NULL
tyrosine	NULL
kinases	NULL
and	NULL
a	NULL
serine/threonine	NULL
kinase	NULL
distinct	NULL
from	NULL
the	NULL
Raf-1/Erk2	NULL
MAP	NULL
kinase	NULL
pathway	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:1902-1913	NULL
.	NULL

3	NULL
.	NULL

Beretta	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
C.	NULL
Gingras	NULL
,	NULL
Y.	NULL
V.	NULL
Svitkin	NULL
,	NULL
M.	NULL
N.	NULL
Hall	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
.	NULL

1996	NULL
.	NULL

Rapamycin	NULL
blocks	NULL
the	NULL
phosphorylation	NULL
of	NULL
4E-BP1	NULL
and	NULL
inhibits	NULL
cap-depen-dent	NULL
initiation	NULL
of	NULL
translation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:658-664	NULL
.	NULL

4	NULL
.	NULL

Botz	NULL
,	NULL
J.	NULL
,	NULL
K.	NULL
Zerfass-Thome	NULL
,	NULL
D.	NULL
Spitzovsky	NULL
,	NULL
H.	NULL
Delius	NULL
,	NULL
B.	NULL
Vogt	NULL
,	NULL
M.	NULL
Eilers	NULL
,	NULL
A.	NULL
Hatzigeorgiou	NULL
,	NULL
and	NULL
P.	NULL
Jansen-Durr	NULL
.	NULL

1996	NULL
.	NULL

Cell	NULL
cycle	NULL
regulation	NULL
of	NULL
the	NULL
murine	NULL
cyclin	NULL
E	NULL
gene	NULL
depends	NULL
on	NULL
an	NULL
E2F	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3401-3409	NULL
.	NULL

5	NULL
.	NULL

Brennan	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
W.	NULL
Babbage	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
Burgering	NULL
,	NULL
B.	NULL
Groner	NULL
,	NULL
K.	NULL
Reif	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
controls	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
interleukin-2	NULL
.	NULL

Immunity	NULL
7:679-689	NULL
.	NULL

6	NULL
.	NULL

Brown	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
M.	NULL
W.	NULL
Albers	NULL
,	NULL
T.	NULL
B.	NULL
Shin	NULL
,	NULL
K.	NULL
Ichikawa	NULL
,	NULL
C.	NULL
T.	NULL
Keith	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
Schreiber	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
mammalian	NULL
protein	NULL
targeted	NULL
by	NULL
Gl-arresting	NULL
rapamycin-receptor	NULL
complex	NULL
.	NULL

Nature	NULL
369:756-758	NULL
.	NULL

7	NULL
.	NULL

Brunn	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
C.	NULL
C.	NULL
Hudson	NULL
,	NULL
A.	NULL
Sekulic	NULL
,	NULL
J.	NULL
M.	NULL
Williams	NULL
,	NULL
H.	NULL
Hosoi	NULL
,	NULL
P.	NULL
J.	NULL
Houghton	NULL
,	NULL
J.	NULL
C.	NULL
J.	NULL
Lawrence	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Abraham	NULL
.	NULL

1997	NULL
.	NULL

Phosphorylation	NULL
of	NULL
the	NULL
translational	NULL
repressor	NULL
PHAS-I	NULL
by	NULL
the	NULL
mammalian	NULL
target	NULL
of	NULL
rapamycin	NULL
.	NULL

Science	NULL
277:99-101	NULL
.	NULL

8	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Smith	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
interleukin-2	NULL
T-cell	NULL
system	NULL
:	NULL
a	NULL
new	NULL
cell	NULL
growth	NULL
model	NULL
.	NULL

Science	NULL
224:1312-1316	NULL
.	NULL

9	NULL
.	NULL

Chen	NULL
,	NULL
Y.	NULL
,	NULL
E.	NULL
S.	NULL
Knudsen	NULL
,	NULL
and	NULL
J.	NULL
Y.	NULL
Wang	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
RB/p107/p130	NULL
phosphorylation	NULL
pathway	NULL
is	NULL
not	NULL
inhibited	NULL
in	NULL
rapamycin-induced	NULL
G1-prolongation	NULL
of	NULL
NIH3T3	NULL
cells	NULL
.	NULL

Oncogene	NULL
13:1765-1771	NULL
.	NULL

10	NULL
.	NULL

Dennis	NULL
,	NULL
P.	NULL
B.	NULL
,	NULL
S.	NULL
Fumagalli	NULL
,	NULL
and	NULL
G.	NULL
Thomas	NULL
.	NULL

1999	NULL
.	NULL

Target	NULL
of	NULL
rapamycin	NULL
(	NULL
TOR	NULL
)	NULL
:	NULL
balancing	NULL
the	NULL
opposing	NULL
forces	NULL
of	NULL
protein	NULL
synthesis	NULL
and	NULL
degradation	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

949-54	NULL
.	NULL

11	NULL
.	NULL

Fairhurst	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
M.	NULL
Daeipour	NULL
,	NULL
M.	NULL
C.	NULL
Amaral	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Nel	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase/ERK-2	NULL
in	NULL
phytohaemagglutinin	NULL
in	NULL
blasts	NULL
by	NULL
recombinant	NULL
interleukin-2	NULL
:	NULL
contrasting	NULL
features	NULL
with	NULL
CD3	NULL
activation	NULL
.	NULL

Immunology	NULL
79:112-118	NULL
.	NULL

12	NULL
.	NULL

Genot	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
P.	NULL
J.	NULL
Parker	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1995	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
role	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
Ca	NULL
,	NULL
e	NULL
,	NULL
and	NULL
{	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:9833-9839	NULL
.	NULL

13	NULL
.	NULL

Hamel	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
R.	NULL
M.	NULL
Gill	NULL
,	NULL
R.	NULL
A.	NULL
Phillips	NULL
,	NULL
and	NULL
B.	NULL
L.	NULL
Gallie	NULL
.	NULL

1992	NULL
.	NULL

Regions	NULL
controlling	NULL
hyperphosphorylation	NULL
and	NULL
conformation	NULL
of	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
are	NULL
independent	NULL
of	NULL
domains	NULL
required	NULL
for	NULL
transcriptional	NULL
re-pression	NULL
.	NULL

Oncogene	NULL
7:693-701	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37.	NULL
p70°	NULL
``	NULL
,	NULL
RAPAMYCIN	NULL
,	NULL
AND	NULL
E2F	NULL
-	NULL
4737	NULL
Hashemolhosseini	NULL
,	NULL
S.	NULL
,	NULL
Y.	NULL
Nagamine	NULL
,	NULL
S.	NULL
J.	NULL
Morley	NULL
,	NULL
S.	NULL
Desriviéres	NULL
,	NULL
L.	NULL
Mercep	NULL
,	NULL
and	NULL
S.	NULL
Ferrari	NULL
.	NULL

1998	NULL
.	NULL

Rapamycin	NULL
inhibition	NULL
of	NULL
the	NULL
G1	NULL
to	NULL
S	NULL
transition	NULL
is	NULL
mediated	NULL
by	NULL
effects	NULL
on	NULL
cyclin	NULL
D1	NULL
mRNA	NULL
and	NULL
protein	NULL
stability	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:14424-14429	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
1998	NULL
.	NULL

Regulation	NULL
of	NULL
cell	NULL
proliferation	NULL
by	NULL
the	NULL
E2F	NULL
transcription	NULL
factors	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

8:28-35	NULL
.	NULL

Hori	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Uchiyama	NULL
,	NULL
M.	NULL
Tsudo	NULL
,	NULL
H.	NULL
Umadome	NULL
,	NULL
H.	NULL
Ohno	NULL
,	NULL
S.	NULL
Fukuhara	NULL
,	NULL
K.	NULL
Kita	NULL
,	NULL
and	NULL
H.	NULL
Uchino	NULL
.	NULL

1987	NULL
.	NULL

Establishment	NULL
of	NULL
an	NULL
interleukin-2-dependent	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
T	NULL
cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
who	NULL
is	NULL
not	NULL
infected	NULL
with	NULL
human	NULL
T	NULL
cell	NULL
leukemia/lymphoma	NULL
virus	NULL
.	NULL

Blood	NULL
70:1069-1072	NULL
.	NULL

Hou	NULL
,	NULL
J.	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
W.	NULL
J.	NULL
Henzel	NULL
,	NULL
S.	NULL
C.	NULL
Wong	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
and	NULL
purification	NULL
of	NULL
human	NULL
Stat	NULL
proteins	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
interleukin-2	NULL
.	NULL

Immunity	NULL
2:321-329	NULL
.	NULL

Izquierdo	NULL
Pastor	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Reif	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
p2iras	NULL
during	NULL
T-cell	NULL
activation	NULL
and	NULL
growth	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16:159-164	NULL
.	NULL

Jefferies	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
S.	NULL
Fumagalli	NULL
,	NULL
P.	NULL
B.	NULL
Dennis	NULL
,	NULL
C.	NULL
Reinhard	NULL
,	NULL
R.	NULL
B.	NULL
Pearson	NULL
,	NULL
and	NULL
G.	NULL
Thomas	NULL
.	NULL

1997	NULL
.	NULL

Rapamycin	NULL
suppresses	NULL
5°	NULL
TOP	NULL
mRNA	NULL
translation	NULL
through	NULL
inhibition	NULL
of	NULL
p70s6k	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:3693-3704	NULL
.	NULL

Johnston	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Kawamura	NULL
,	NULL
R.	NULL
Kirken	NULL
,	NULL
Y.	NULL
Chen	NULL
,	NULL
T.	NULL
Blake	NULL
,	NULL
K.	NULL
Shibuya	NULL
,	NULL
J.	NULL
Ortaldo	NULL
,	NULL
D.	NULL
McVicar	NULL
,	NULL
and	NULL
J.	NULL
O'Shea	NULL
.	NULL

1994	NULL
.	NULL

Phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
Jak-3	NULL
Janus	NULL
kinase	NULL
in	NULL
response	NULL
to	NULL
interleukin-2	NULL
.	NULL

Nature	NULL
370:151-153	NULL
.	NULL

Johnston	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
C.	NULL
M.	NULL
Bacon	NULL
,	NULL
D.	NULL
S.	NULL
Finbloom	NULL
,	NULL
R.	NULL
C.	NULL
Rees	NULL
,	NULL
D.	NULL
Kaplan	NULL
,	NULL
K.	NULL
Shibuya	NULL
,	NULL
J.	NULL
R.	NULL
Ortaldo	NULL
,	NULL
S.	NULL
Gupta	NULL
,	NULL
Y.	NULL
Q.	NULL
Chen	NULL
,	NULL
J.	NULL
D.	NULL
Giri	NULL
,	NULL
and	NULL
J.	NULL
O'Shea	NULL
.	NULL

1995	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Stat5	NULL
,	NULL
Stat3	NULL
,	NULL
and	NULL
Janus	NULL
kinases	NULL
by	NULL
interleukin-2	NULL
and	NULL
interleukin-15	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:8705-8709	NULL
.	NULL

Karnitz	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
L.	NULL
A.	NULL
Burns	NULL
,	NULL
S.	NULL
L.	NULL
Sutor	NULL
,	NULL
J.	NULL
Blenis	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Abraham	NULL
.	NULL

1995	NULL
.	NULL

Interleukin-2	NULL
triggers	NULL
a	NULL
novel	NULL
phosphatidylinositol	NULL
3-kinase-dependent	NULL
MEK	NULL
activation	NULL
pathway	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:3049-3057	NULL
.	NULL

Kawasame	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
Papst	NULL
,	NULL
S.	NULL
Webb	NULL
,	NULL
G.	NULL
M.	NULL
Keller	NULL
,	NULL
G.	NULL
L.	NULL
Johnson	NULL
,	NULL
E.	NULL
W.	NULL
Gelfand	NULL
,	NULL
and	NULL
N.	NULL
Terada	NULL
.	NULL

1998	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
p70S6k	NULL
defines	NULL
its	NULL
role	NULL
in	NULL
protein	NULL
synthesis	NULL
and	NULL
rapamycin	NULL
sensitivity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:5033-5038	NULL
.	NULL

Lin	NULL
,	NULL
J.-X	NULL
.	NULL

,	NULL
T.-S.	NULL
Migone	NULL
,	NULL
M.	NULL
Tsang	NULL
,	NULL
M.	NULL
Friedmann	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Weatherbee	NULL
,	NULL
L.	NULL
Zhou	NULL
,	NULL
A.	NULL
Yamauchi	NULL
,	NULL
E.	NULL
T.	NULL
Bloom	NULL
,	NULL
J.	NULL
Mictz	NULL
,	NULL
S.	NULL
John	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
role	NULL
of	NULL
shared	NULL
receptor	NULL
motifs	NULL
and	NULL
common	NULL
Stat	NULL
proteins	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
cytokine	NULL
pleiotropy	NULL
and	NULL
redundancy	NULL
by	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-13	NULL
,	NULL
and	NULL
IL-15	NULL
.	NULL

Immunity	NULL
2331-339	NULL
.	NULL

Loeken	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
J.	NULL
Brady	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
adenovirus	NULL
EIIA	NULL
enhancer	NULL
.	NULL

Analysis	NULL
of	NULL
regulatory	NULL
sequences	NULL
and	NULL
changes	NULL
in	NULL
binding	NULL
activity	NULL
of	NULL
ATF	NULL
and	NULL
EIF	NULL
following	NULL
adenovirus	NULL
infection	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:6572-6579	NULL
.	NULL

Mann	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
N.	NULL
C.	NULL
Jones	NULL
.	NULL

1996	NULL
.	NULL

E2F-1	NULL
but	NULL
not	NULL
E2F-4	NULL
can	NULL
overcome	NULL
pl6-induced	NULL
G1	NULL
cell-cycle	NULL
arrest	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

6:474-483	NULL
.	NULL

Meyuhas	NULL
,	NULL
O.	NULL
,	NULL
D.	NULL
Avai	NULL
,	NULL
and	NULL
S.	NULL
Shama	NULL
.	NULL

1996	NULL
.	NULL

Translational	NULL
control	NULL
of	NULL
ribosomal	NULL
protein	NULL
mRNAs	NULL
in	NULL
eukaryotes	NULL
,	NULL
p.	NULL
363-388	NULL
.	NULL

In	NULL
J.	NULL
W.	NULL
B.	NULL
Hershey	NULL
,	NULL
M.	NULL
B.	NULL
Matthews	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Translational	NULL
control	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Ming	NULL
,	NULL
X.-F.	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
Burgering	NULL
,	NULL
S.	NULL
Wennstrom	NULL
,	NULL
L.	NULL
Claesson-Welsh	NULL
,	NULL
C.-H.	NULL
Heldin	NULL
,	NULL
J.	NULL
L.	NULL
Bos	NULL
,	NULL
S.	NULL
C.	NULL
Kozma	NULL
,	NULL
and	NULL
G.	NULL
Thomas	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
p70/p85	NULL
S6	NULL
kinase	NULL
by	NULL
a	NULL
pathway	NULL
independent	NULL
of	NULL
p21ras	NULL
.	NULL

Nature	NULL
371:426-429	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
Y.	NULL
Nakagawa	NULL
,	NULL
Y.	NULL
Minami	NULL
,	NULL
Z.-J	NULL
.	NULL

Lin	NULL
,	NULL
I.	NULL
Oishi	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
B.	NULL
Witthuhn	NULL
,	NULL
J.	NULL
Ihle	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
activation	NULL
of	NULL
Jak1	NULL
and	NULL
Jak3	NULL
by	NULL
selective	NULL
association	NULL
with	NULL
IL-2	NULL
receptor	NULL
subunits	NULL
.	NULL

Science	NULL
266:1045-1047	NULL
.	NULL

Moberg	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
A.	NULL
Starz	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Lees	NULL
.	NULL

1996	NULL
.	NULL

E2F-4	NULL
switches	NULL
from	NULL
p130	NULL
to	NULL
p107	NULL
and	NULL
pRB	NULL
in	NULL
response	NULL
to	NULL
cell	NULL
cycle	NULL
reentry	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:1436-1449	NULL
.	NULL

Murthy	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
G.	NULL
P.	NULL
Bhat	NULL
,	NULL
and	NULL
B.	NULL
Thimmappaya	NULL
.	NULL

1985	NULL
.	NULL

Adenovirus	NULL
EIIA	NULL
early	NULL
promoter	NULL
:	NULL
transcriptional	NULL
control	NULL
elements	NULL
and	NULL
induction	NULL
by	NULL
the	NULL
viral	NULL
pre-early	NULL
EIA	NULL
gene	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
sequence	NULL
independent	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:2230-2234	NULL
.	NULL

Nourse	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Firpo	NULL
,	NULL
W.	NULL
M.	NULL
Flanagan	NULL
,	NULL
S.	NULL
Coats	NULL
,	NULL
K.	NULL
Polyak	NULL
,	NULL
M.	NULL
H.	NULL
Lee	NULL
,	NULL
J.	NULL
Massague	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-2-mediated	NULL
elimination	NULL
of	NULL
the	NULL
p27Kip1	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
prevented	NULL
by	NULL
rapamycin	NULL
.	NULL

Nature	NULL
372:570-573	NULL
.	NULL

Ohtani	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
properties	NULL
of	NULL
a	NULL
Drosophila	NULL
homolog	NULL
of	NULL
the	NULL
E2F1	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1603-1612	NULL
.	NULL

Reif	NULL
,	NULL
K.	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
Burgering	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
links	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
to	NULL
protein	NULL
kinase	NULL
B	NULL
and	NULL
p70	NULL
S6	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:14426-14438	NULL
.	NULL

Reif	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
D.	NULL
Nobes	NULL
,	NULL
G.	NULL
Thomas	NULL
,	NULL
A	NULL
.	NULL

Hall	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1996	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
signals	NULL
activate	NULL
a	NULL
selective	NULL
subset	NULL
of	NULL
Rac/Rho-de-pendent	NULL
effector	NULL
pathways	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

6:1445-1455	NULL
.	NULL

Remillard	NULL
,	NULL
B.	NULL
,	NULL
R.	NULL
Petrillo	NULL
,	NULL
W.	NULL
Maslinski	NULL
,	NULL
M.	NULL
Tsudo	NULL
,	NULL
T.	NULL
B.	NULL
Strom	NULL
,	NULL
L.	NULL
Cantley	NULL
,	NULL
and	NULL
L.	NULL
Varticovski	NULL
.	NULL

1991	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
regulates	NULL
activation	NULL
of	NULL
phosphatidylinositol	NULL
3-kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:14167-14170	NULL
.	NULL

Russell	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Johnston	NULL
,	NULL
M.	NULL
Noguchi	NULL
,	NULL
M.	NULL
Kawamura	NULL
,	NULL
C.	NULL
Bacon	NULL
,	NULL
M.	NULL
Fried-man	NULL
,	NULL
M.	NULL
Berg	NULL
,	NULL
D.	NULL
McVicar	NULL
,	NULL
B.	NULL
Witthuhn	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
A.	NULL
Goldman	NULL
,	NULL
F.	NULL
Schmalstieg	NULL
,	NULL
J.	NULL
Ihle	NULL
,	NULL
J.	NULL
O'Shea	NULL
,	NULL
and	NULL
W.	NULL
Leonard	NULL
.	NULL

1994	NULL
.	NULL

Interaction	NULL
of	NULL
IL-2R	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
with	NULL
Jak1	NULL
and	NULL
Jak3	NULL
:	NULL
implications	NULL
for	NULL
XSCID	NULL
and	NULL
XCID	NULL
.	NULL

Science	NULL
266:1042-1045	NULL
.	NULL

4738	NULL
38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

BRENNAN	NULL
ET	NULL
AL	NULL
.	NULL

Sabatini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
H.	NULL
Erdjumentbromage	NULL
,	NULL
M.	NULL
Lui	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Snyder	NULL
.	NULL

1994	NULL
.	NULL

Raftl-a	NULL
mammalian	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
FKBP12	NULL
in	NULL
a	NULL
rapamycin-dependent	NULL
fashion	NULL
and	NULL
is	NULL
homologous	NULL
to	NULL
yeast	NULL
Tors	NULL
.	NULL

Cell	NULL
78:35-43	NULL
.	NULL

Sheaff	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
Groudine	NULL
,	NULL
M.	NULL
Gordon	NULL
,	NULL
J.	NULL
M.	NULL
Roberts	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Clurman	NULL
.	NULL

1997	NULL
.	NULL

Cyclin	NULL
E-CDK2	NULL
is	NULL
a	NULL
regulator	NULL
of	NULL
p27Kip1	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:1464-1478	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
,	NULL
R.	NULL
Wang	NULL
,	NULL
A.	NULL
Sharma	NULL
,	NULL
C.	NULL
Gao	NULL
,	NULL
M.	NULL
Collins	NULL
,	NULL
L.	NULL
Penn	NULL
,	NULL
and	NULL
G.	NULL
B	NULL
.	NULL

Mills	NULL
.	NULL

1997	NULL
.	NULL

Dissociation	NULL
of	NULL
cytokine	NULL
signals	NULL
for	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:5318-5328	NULL
.	NULL

Shima	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Pende	NULL
,	NULL
Y.	NULL
Chem	NULL
,	NULL
S.	NULL
Fumagalli	NULL
,	NULL
G.	NULL
Thomas	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Kozma	NULL
.	NULL

1998	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
p70S6k/p85S6k	NULL
gene	NULL
reveals	NULL
a	NULL
small	NULL
mouse	NULL
phenotype	NULL
and	NULL
a	NULL
new	NULL
functional	NULL
S6	NULL
kinase	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:6649-6659	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1985	NULL
.	NULL

Interleukin	NULL
2	NULL
regulates	NULL
its	NULL
own	NULL
receptors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:864-868	NULL
.	NULL

Terada	NULL
,	NULL
N.	NULL
,	NULL
K.	NULL
Takase	NULL
,	NULL
P.	NULL
Papst	NULL
,	NULL
A.	NULL
Nairn	NULL
,	NULL
and	NULL
E.	NULL
Gelfand	NULL
.	NULL

1995	NULL
.	NULL

Rapamycin	NULL
44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

inhibits	NULL
ribosomal	NULL
protein	NULL
synthesis	NULL
and	NULL
induces	NULL
G1	NULL
prolongation	NULL
in	NULL
mitogen	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:3418-3426	NULL
.	NULL

Thomas	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
M.	NULL
N.	NULL
Hall	NULL
.	NULL

1997	NULL
.	NULL

TOR	NULL
signalling	NULL
and	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:782-787	NULL
.	NULL

Turner	NULL
,	NULL
B.	NULL
,	NULL
U.	NULL
Rapp	NULL
,	NULL
H.	NULL
App	NULL
,	NULL
M.	NULL
Greene	NULL
,	NULL
K.	NULL
Dobashi	NULL
,	NULL
and	NULL
J.	NULL
Reid	NULL
.	NULL

1991	NULL
.	NULL

Interleukin-2	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
p72-74	NULL
Raf-1	NULL
kinase	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:1227-1232	NULL
.	NULL

Von	NULL
Manteuffel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
A.	NULL
C.	NULL
Gingras	NULL
,	NULL
X.	NULL
F.	NULL
Ming	NULL
,	NULL
N.	NULL
Sonenberg	NULL
,	NULL
and	NULL
G.	NULL
Thomas	NULL
.	NULL

1996	NULL
.	NULL

4E-BP1	NULL
phosphorylation	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
Frap-p70	NULL
S6	NULL
kinase	NULL
pathway	NULL
and	NULL
is	NULL
independent	NULL
of	NULL
mitogen-activated	NULL
protein-kinase	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:4076-4080	NULL
.	NULL

Witthubn	NULL
,	NULL
B.	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
Miura	NULL
,	NULL
K.	NULL
Lai	NULL
,	NULL
C.	NULL
Cwik	NULL
,	NULL
E.	NULL
Liu	NULL
,	NULL
and	NULL
J.	NULL
Thle	NULL
.	NULL

1994	NULL
.	NULL

Involvement	NULL
of	NULL
the	NULL
Jak-3	NULL
Janus	NULL
kinase	NULL
in	NULL
signalling	NULL
by	NULL
interleukins	NULL
2	NULL
and	NULL
4	NULL
in	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cells	NULL
.	NULL

Nature	NULL
370:153-157	NULL
.	NULL

